

5

Exemplary web site according to a preferred embodiment of the present invention

10

[illegible]



Please make sure you enter your e-mail address properly!

Submit Information

Please Bookmark this Page (contl-d) for future reference



**BUSINESS COMBINATION
OPPORTUNITY
SALE – MERGER – ACQUISITION**

(OTC: CIST)



- **Strong Cash Position**
- **Promising Research Collaboration with Big Pharma**
- **Strong Intellectual Property Position**
- **Technology with BLOCK BUSTER POTENTIAL with Underlying Proof of Concept Trials in Humans (arthritis)**
- **Technology has Orphan Disease Applications (Multiple Myeloma/GVHD)**
- **Largest Asset: Monoclonal Antibody/ IL-1B**

Genome Securities, Inc. has been retained by Cistron Biotechnology, Inc. in connection with this transaction. All questions concerning this business opportunity with the Company and any of its core technologies presented within these web pages should be directed to Genome Securities, Inc.

Proposals should contain the following information:

- Type of transaction envisioned
- Synergy of Cistron's technologies with development plans
- Ability to execute plan
- Other pertinent information

Under no circumstances should the Company, their employees or customers be contacted directly.

For more information contact:

Robert Naismith, Ph.D.

Genome Securities, Inc.

800 James Avenue

Suite 201

Scranton, PA 18510-1544

rwn@genomesecurities.com

The information contained in this document was obtained from the Company and other public sources. Any information contained herein has been compiled by Genome Securities, Inc. and involves significant elements of subjective judgment and analysis, which may or may not be correct. Neither the Company nor Genome Securities, Inc. make any representation or warranty, expressed or implied, as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon as a promise or representation, whether as to the past or the future. This document does not purport to contain all of the information that may be required to evaluate such transaction and any recipient hereof should conduct its own independent analysis of the Company and the data contained or referred to herein. Genome Securities, Inc. has not independently verified any of such information and assumes no responsibility for its accuracy or completeness.

Last Updated 11/09/99

- **Cistron Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**
- **Home**

Visit our future
site for online
trading



T0030-2829860




Transaction Rationale

While the Company is committed to furthering its development efforts in the areas of vaccines, adjuvants and therapeutics, it believes that its best alternative for maximizing shareholder value for its portfolio of technologies are through a strategic transaction to include a merger, acquisition or other business combination. Accordingly, Genome Securities, Inc. has been retained to explore alternatives for the Company. Cistron is generally flexible regarding the structure of the transaction and is willing to consider certain requirements of the purchaser in order to facilitate a timely and non-disruptive transaction. An ideal business combination would include Cistron combining its assets with another company to exploit and commercialize its technology and thereby benefit its shareholders. Although the Company prefers one transaction of its portfolio of technologies, Cistron is willing to consider the sale of individual technologies where deemed reasonable. In addition, consideration for the transaction may vary between cash, registered stock or a combination thereof.

Genome Securities, Inc. has been exclusively retained by Cistron in connection with this transaction for the purpose of undertaking a business combination of the company as presented herein. Any questions concerning this presentation and the opportunity to acquire Cistron or any of its core technologies presented within this presentation should be directed to Genome Securities, Inc.

05/30/2000 10:42 AM

Cistron Biotechnology, Inc. Pine Brook, NJ 07058



Purpose: To determine whether mouse monoclonal IC8 is able to neutralize activity of human IL-1 β in a bioassay.

Dilutions of recombinant human IL-1 β (Cistrion) were prepared in medium with or without IC8 monoclonal anti-IL-1 β antibody.

D10.G4.1 cells (ATCC) were cultured with the IL-1 β dilutions for 64 hours, in the presence of a submitogenic concentration of conA. XTT and PMS were added, and absorbance at 450 nm was measured after 4 hours. [References: American Type Culture Collection, Rockville, MD; D.A. Scudiero, et al.(1988) *Cancer Research* 48:4827-4833.]

Result and Conclusion: Addition of IC8 monoclonal to the IL-1 bioassay resulted in a loss of signal (see figure). IC8 neutralized biological activity of human IL-1 β .

● **Antibody in Bioassay**

● **Antibody in Animals**

● **Antibody with Plasma**

● **With Human Cartilage**

● **IL-1 β -mab in Cartilage**

● **Publications**

● **Anti Tumour Effects**

● **Biological Properties**

● **Effects of Treatment**

● **Treatment RA**

● **Antibody in Bioassay**

● **Antibody in Animals**

● **Antibody with Plasma**

● **With Human Cartilage**

● **IL-1 β -mab in Cartilage**

● **Publications**

● **Anti Tumour Effects**

● **Biological Properties**

● **Effects of Treatment**

● **Treatment RA**

Visit our future
site for online
trading





Therapeutic Potential

***Genome Securities was assisted
by the following investigators in
compiling this information***

Ashok R. Amin, Ph.D.
Hospital for Joint Diseases
Mount Sinai-NYU
Medical Center & Health System
301 East 17th Street
New York, NY 10003

Charles A. Dinarello, M.D.
Professor of Medicine
University of Colorado
School of Medicine

Richard S. Dondero
Cistron Biotechnology
10 Bloomfield Ave.
Pine Brook, NJ 07058

John A. Lust, M.D., Ph.D.
Mayo Clinic Rochester
200 First Street Southwest
Rochester, Minnesota 55905

Lanny J. Rosenwasser, M.D.
National Jewish Medical and
Research Center
1400 Jackson Street
Denver, Co 80206

09367882-053004
T00E9D-288Z9860

- [REDACTED]
- [REDACTED]
- [REDACTED]
- Therapeutic Targets
 - Why Inhibit IL-1
 - IL-1 β versus IL-1 α
 - Differences Between IL-1 α & IL-1 β
 - IL-1 β & Host Defense Mechanisms
 - Evidence that IL-1 β Mediates bone Resorption
 - Anti-cytokine-based Therapies
 - Future of Anti-Cytokine Therapies
 - Blocking IL-1 in RA
 - Multiple Myeloma
 - GVHD
 - Asthma
 - Role of IL-1 in Osteo
 - Other Possible Therapeutic Applications
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

Visit our future
site for online
trading



0966788228929850



Research Collaboration



Pasteur Merieux Connaught
Abstracted from Chemical Market Reporter 08/03/98

Pasteur Merieux Connaught to invest in Interleukin-1 beta vaccine adjuvant development program with Cistron Biotechnology Inc; latter could receive up to \$31 mil in milestone payments plus royalties

On June 30, 1998, Cistron and Pasteur Merieux Serums & Vaccins, S.A. (PMS&V), the world's largest vaccine company, entered into a letter of intent for an option and license agreement pertaining to the use of IL-1 as a vaccine adjuvant in the fields of preventive and therapeutic vaccines. On October 30, 1998, PMS&V purchased 1,333,333 shares of Cistron common stock at approximately \$.75 per share and received warrants to purchase 666,667 additional shares at \$.25 per share, for an aggregate price of \$1,000,000. BlueStone Capital is entitled to a fee from Cistron of 7% of this transaction and to receive an additional warrant to purchase 400,000 shares of common stock at \$.25 per share. Simultaneously, the parties also entered into an option and collaboration agreement, under which PMS&V obtained a three-year option to acquire an exclusive license to use Cistron's interleukin-1 beta technology in the fields of therapeutic and preventive vaccines. Under that agreement, PMS&V also agreed to fund Cistron's vaccine adjuvant development program over the three-year period for \$900,000. The agreement contemplates that PMS&V will conduct its own preclinical and clinical work on the use of IL-1 beta as a vaccine adjuvant in these fields. If the option is exercised, Cistron could receive an aggregate of \$31 million in milestone payments based upon the development progress of adjuvanted vaccine products using Cistron's IL-1 beta technology or joint technology developed by the parties, through clinical trials and FDA approvals, provided PMS&V exercises all its rights under the agreement and subject to completion of the development program as currently contemplated. Cistron would also receive royalties should PMS&V sell vaccines using that technology. There can be no assurance that PMS&V will exercise its option to license IL-1 adjuvant rights or if they do, that product development milestones will be achieved.



Royalty Agreements

Techne Acquires Cistron Biotechnology's Research Reagents Business and Exclusive Sublicense to Certain Interleukin 1 Beta Patents for the Research Market

Tuesday, February 23, 1999 10:08 AM

MINNEAPOLIS, Feb. 23 /PRNewswire/ -- Techne Corporation (Nasdaq: TECH) and Cistron Biotechnology, Inc. (OTC Bulletin Board: CIST) announced today that through TECHNE's subsidiary, Research and Diagnostics Systems, Inc. (R&D Systems), TECHNE has purchased from Cistron its research reagents business and exclusive research market rights to Interleukin 1 beta (IL-1B) antibody and immunoassay patents. Cistron will retain diagnostic and therapeutic marketing rights on the IL-1B patents.

The effective date of the acquisition is April 1, 1999. R&D Systems paid \$750,000 cash for Cistron's research reagents business and IL-1B research market patent rights. In addition, royalties will be paid on the net sales of IL-1B proteins, antibodies and immunoassays by TECHNE and its subsidiaries for the life of the patents. Cistron's research reagent sales for their fiscal year ended June 30, 1998 were approximately \$550,000.

Thomas E. Oland, President of TECHNE said, "We have had a working relationship with Cistron for a number of years and we were very pleased that they came to us when they decided to withdraw from the research reagents market place. We believe we are the leaders in the cytokine research reagents market and that we will be able to maximize Cistron's royalty stream on sales of IL-1B."

Bruce C. Galton, Chairman and CEO of Cistron said, "Cistron is concentrating on the research and development of the therapeutic and diagnostic applications of our technologies rather than continue the production and sale of research reagents. R&D Systems was a natural choice to work with for the research product market due to their scientific strength and marketing expertise."

Cistron's primary product area is immune response regulators known as lymphokines. The company is developing therapeutic and diagnostic applications of its technology for cancer, arthritis and other autoimmune diseases.

TECHNE Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe Ltd. of Abingdon England. R&D Systems is a specialty manufacturer of biological products and R&D Systems Europe is a distributor of biotechnology products.

SOURCE Techne Corporation

CONTACT: Kathy Backes of Techne Corporation, 612-627-0394

© 1999, PR Newswire



Cistron settles with Immunex.

Abstracted from **Nature Biotechnology** 12/96

Cistron Biotechnology Inc. (Pine Brook, NJ) settled its dispute over ownership of interleukin-1 beta by accepting \$21 million in cash and two patents from Immunex Corp. (Seattle, WA). Cistron had claimed that an Immunex executive passed on information about interleukin-1 beta to his researchers after reading a manuscript given to him for peer review. In giving up the patents for the active form of the substance and its purification, Immunex avoids harsher financial damages and close scrutiny of its actions. The settlement before trial means the interesting issue of the legal and financial responsibilities of peer reviewers will not yet come before a judge.

10030-233/9950



R&D: Cistron

Client: New England Medical Center,
Tufts University, MIT, Wellesley

Date: 12/83

Parties: University / Biotech

Type: Research, License

Subject: Human IL-1 cloning

\$ Terms: Full

Disease:

Autoimmune - Immunomodulators

Size (\$M): \$1.1

Technology:

Recombinant DNA

Equity

Stage At Signing:

Discovery

(\$M):

Royalty: 7%

096593-03001
T00000-23979860



Patent Protection

Company investigators, both at universities and in-house, seek patent protection for technology when deemed appropriate and have filed applications for U.S. and foreign patents relating to several different products and processes. Between 1988 and 1997, seven patents containing claims directed to various aspects of human IL-1 technology and one directed to the PAI-2 DNA were issued to the Institutions, from which the Company received an exclusive worldwide license. The European equivalent patent was issued in December 1993 and the Japanese equivalent in 1997. In December 1995, a U.S. patent related to the Company's assay was issued. In addition to the issued IL-1 patents, a number of applications of the Institutions and Cistron are pending in the U.S. and foreign countries covering an inhibitor to IL-1, certain IL-1 uses, IL-1 Antibodies, and additional claims for the IL-1 Assay. The Company was assigned rights to certain issued IL-1 U.S. patents of Immunex as part of litigation settlement. There can be no assurance that the pending applications will result in the issuance of any patents or that the patents issued to date or any future patents issued will provide substantial protection or be of commercial benefit to the Company or to licensees of the technology. The Company is relying upon trade secrets, unpatented proprietary know-how and continuing technological innovation to develop its competitive position. However, there can be no assurance that others may not acquire or independently develop similar technology.

In December 1991, the Company, together with the Institutions, filed suit in U.S. District Court in Newark, New Jersey against PeproTech, Inc., alleging infringement of the Institutions' patent covering the production of recombinant IL-1, to which the Company holds an exclusive license.

In March 1997, the Company and PeproTech settled all outstanding litigation. Under the settlement, PeproTech paid the Company \$718,000 (one-half of which Cistron then paid to the Institutions) for license fees and other expenses. Cistron and PeproTech both withdrew their motions for appeal.

In January 1992, the Company was notified by the Institutions that the U.S. Patent and Trademark Office (the "Patent Office") had declared an interference between a pending application owned by the Institutions and licensed to the Company and a pending application owned by Immunex Corp. ("Immunex"). The subject matter of the interference, as defined by the Patent Office, is "a substantially pure IL-1 beta protein." In October 1993, the Company was notified that the U.S. Patent and Trademark Office Board of Appeals and Interferences had entered a judgment of "no interference in fact" in the interference declared in January 1992 between pending patent claims licensed to the Company by the Institutions and pending patent claims of Immunex Corp. The pending claims were referred back to the original examiners for further review. Claims in the application owned by the Institutions and licensed to the Company that was the subject of the interference were allowed and issued a U.S. Patent No. 5,510,462 in April 1996.

In January 1996, the Patent Office granted U.S. patent No. 5,484,887 (the '887 patent) owned by Immunex. The '887 patent includes claims to purified, mature human IL-1 protein (claims 8-12). In March 1996, a request for reexamination of the '887 patent was filed in the Patent Office. An order granting the request for reexamination of the '887 patent was issued by the Patent Office in May 1996. These patent claims are the subject of an ongoing reexamination proceeding at the U.S. Patent and Trademark Office (PTO), which presently rejects certain claims over scientific literature principally representing prior art considered by the PTO previously, during primary examination. Cistron is seeking to have the rejection withdrawn or overruled on the merits. Cistron also has petitioned to terminate the reexamination as improper, because the PTO relies on prior art invoked during primary examination, contravening what Cistron deems controlling legal precedent. However, as part of settlement of the Company's litigation against Immunex, this patent has been assigned to Cistron.

On September 28, 1993, the Company filed suit in the U.S. District Court, District of New Jersey, against Immunex Corporation alleging misappropriation of trade secrets related to IL-1 and seeking damages therefor.

In November 1996, Cistron and Immunex agreed to settle all Cistron's claims against Immunex and two former Immunex officers. Under the terms of settlement, Immunex agreed to pay Cistron an aggregate of \$21 million (\$11 million November 1996, \$3 million per year in November 1997, 1998, and 1999, and \$1 million in November 2000) and to assign certain IL-1 patents to Cistron. As of the date of this report, Immunex had paid Cistron the installments due in November 1996 and 1997.



Licenses

Cistron has an exclusive, worldwide license from the Institutions to make, use and sell, and to sublicense to others, products adapting the IL-1 Patents and to make, use and sell products incorporating related technology. The Company was granted this license in return for funding the research and development resulting in the issuance to the Institutions of the IL-1 Patents. The term of such license is the life of the IL-1 Patents, with respect to the patents, and October 1, 2000, in the case of the related technology, in each case excluding any time required for pre-market clearance that may be required by a U.S. regulatory agency. The Company pays a royalty on IL-1 sales to the Institutions. If the Company enters into a joint venture with another company to commercialize IL-1, the Company must pay a royalty to the Institutions on sales to the joint venture partner and royalties received from such partner. If the Company enters into sublicense arrangements with other companies that are not joint ventures, the Company must pay a royalty of 50% of royalties received from the sublicensee. Cistron has been involved in litigation and a patent regulatory proceeding in order to protect its rights to the IL-1 Patents from infringement..

05/30/2000 10:44 AM

**U.S. Patents Issued**

Docket No./ Serial No./ Patent No.	Title	Inventor(s)	Date Issued/ Date Filed	Maintenance Fees Due	Patent Expires
C-100.FWC3 08/164,283 <u>5,474,899</u>	Selective Immunoassay for IL- β	Peter J. Lisi	12/12/95 12/7/93	6/12/99 6/12/03 6/12/07	12/7/2013
C-100F3DI 08/570,074 <u>5,789,185</u>	Selective Immunoassay for IL- β	Peter J. Lisi	8/4/98 12/11/95	2/4/02 2/4/06 2/4/10	12/7/2013 (terminally disclaimed over C-100.FWC3)
C-0303C 06/676,533 <u>5,484,887</u> ¹	Homogenous Interleukin 1	Shirley A. Kronheim Carl J. March Paul J. Conlon, III Thomas P. Hopp	1/16/96 11/30/84	7/16/99 7/16/03 7/16/07	1/16/2013
C-0305B 07/443,399 <u>5,122,459</u>	The Gene Encoding Biologically Active Human Interleukin 1	Paul J. Conlon III David J. Cosman Kenneth H. Grabstein Thomas P. Hopp Shirley R. Kronheim Alf D. Larsen Carl J. March Virginia L. Price Douglas P. Cerretti	6/16/92 11/30/89	12/16/95 12/16/99 12-16/03	6/16/2009
¹ Subject of Reexamination Proceeding No. 90/004,176 (Docket No. C-R1)					

NEM100 C1.D1. <u>5,001,057</u>	Truncated Human IL-10 CDNA Sequences Encoding Biologically Active Human IL-1 Proteins	Philip E. Auron Andrew C. Webb Lee Gehrke Charles A. Dinarello Lanny Rosenwasser Alexander Rich Sheldon M. Wolff	3/19/91 4/21/88	9/19/94 - paid 9/19/98 9/19/02	3/19/2008
NEM100 C1.D1. DI. <u>5,077,219</u>	Truncated Human IL-1 P CDNA Sequences Encoding Biologically Active Human IL-1 Proteins	Philip E. Auron Andrew C. Webb Lee Gehrke Charles A. Dinarello Lanny Rosenwasser Alexander Rich Sheldon M. Wolff	12/31/91 2/16/90	6/30/95 - paid 6/30/99 6/30/03	12/31/2008
NEM200.FWC 07/8871118 <u>5,286,847</u>	IL-1 Biological Inhibitors (muteins of IL-1)	Lee Gehrke Philip E. Auron Lanny J. Rosenwasser	2/15/94 5/19/92	8/15/97 - paid 8/15/01 8/15/05	2/15/2011

NEM100.FWC 07/004,319 <u>4,766,069</u>	Recombinant DNA Which Codes for inteleukin-1	Philip E. Auron Charles A. Dinarello Andrew C. Webb Alexander Rich Sheldon M. Wolff	8/23/88 1/18/87	2/23/92 - paid 2/23/96 - paid 2/23/00	8/23/2005
NEM100FWCD1 07/185,731 (interference No.1021764) <u>5,510,462</u>	IL-1 P Protein Precursor [as amended]	Philip E. Auron Charles A. Dinarello Andrew C. Webb Alexander Rich Sheldon M. Wolff	4/23/96 4/25/88	10/23/99 10/23/03 10/23/07	4/23/2013
NIOOFDD.FWC2 08/071,031 <u>5,681,933</u>	IL-1 0 Antibodies and Proteins	Philip E. Auron Charles A. Dinarello Andrew C. Webb Alexander Rich Sheldon M. Wolff	10/28/97 6/1/93	4/28/01 4/28/05 4/28/09	10/28/2014
NEM100-CI <u>4,762,914</u>	Human IL-1 β cDNA Sequencer, Encoding Biologically Active Human IL-1 β Proteins	Philip E. Auron Andrew C. Webb Lee Gehrke Charles A. Dinarello Lanny J. Rosenwasser Alexander Rich	8/9/88 2/11/85	2/9/92 -paid 2/9/96 -paid 2/9/00	8/9/2005

	Alexander Rich Sheldon M. Wolff			
--	------------------------------------	--	--	--

0967882-034001
T00650-28879860



Status of Foreign Applications

DOCKET NO. NEM100/100.CI

Human IL-10 EDNA Sequences Encoding Biologically-Active Human IL-10 Proteins

Inventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Lee Gehrke and Sheldon M. Wolff (deseasw)

Priority Claimed: U.S. Serial No.: 661,669 (5/18/84)

Where Filed	Date Filed	Application No.	Publication Date/ Publication No.	Status
EPO	May 7, 1985	85303234.0	November 11, 1985 0161901	Patent No. 0161901, granted 12/1/93 Belgium - BE0161901 France - FR0161901 Germany - P3587689 / Great Britain - GBO 161901 Italy - IT0161901 Netherlands - NLO161901 Sweden - SE0161901 Switzerland - PO161901
Japan	May 18, 1985	104978/85	June 8, 1986 119191/88 For Opposition September 3, 1997	Patent No. 2650026, granted 5/16/97.

DOCKET NO. NEM200

IL-1 Biological Inhibitors (mteins of IL-1)

Inventors: Lee Gehrke, Philip C. Auron, Lanny Rosenwasser

Priority Claimed: U.S. Serial No.: 316,278 (2127/89)

Where Filed	Date Filed	Application No.	Publication Date/ Publication No.	Status
EPO Austria, Belgium, Denmark, France, Germany, Great Britain, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland	February 23, 1990 From PCT Application	90904008.1	December 11th 1991 0450052	Patent No. 0450052, granted 04/15/98 Austria - AT 0450052 Belgium - BE 0450052 Denmark - DK 0450052 France - FR0450052 Germany - A waiting Patent No. Great Britain - GB 0450052 Italy - IT 0450052 Luxembourg - LU 0450052 Netherlands - NL 0450052 Spain - ES 0450052 Sweden - SE 0450052 Switzerland - P 0450052
Japan	February 23, 1990 From PCT Application	604068/90	July 2, 1992 603602/93 March 13, 1996 H08-024595	Patent No. 2122040 granted 12/20/96

DOCKET NO. NEM1001100.CI.JAP.DI

Human IL-1 0 CDNA Sequences Encoding Biologically-Active Human IL-1 0 Proteins inventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Lee Gehrke and Sheldon M. Wolff (deceased) Priority Claimed: U.S. Serial No.: 661,669 (5/18/84)

Where Filed	Date Filed	Application No.	Publication Date/ Publication No.	Status
Japan	May 18, 1985	288777/93	November 15, 1994 H06-315393	Patent No. 2805008 granted 7/24/98

DOCKET NO.: C-0305

Purification, Cloning and Characterization of the Gene for Interleukin 1 inventors: Douglas P. Cerretti, Paul J. Conlon, 111, David J. Cosman, Kenneth H. Grabstein, Thomas P. Hopp, Shidey R. Kronheim, Alfred Larsen, Cari-J. March, Virginia L. Price

Priority claimed: U.S. Serial Nos.: 622,201 (6/19/84); 635,006 (7/27/84); 674,55 (11/26/84); 676,533 (11/30/84); 687,646 (12/31/84)

Where Filed	Date Filed	Application No.	Publication Date/ Publication No.	Status
EPO Austria, Belgium, France Germany, Great Britain, Italy, Luxembourg, Netherlands, Sweden, Switzerland	March 13, 1985	85301752.3	December 27, 1985 0165654	Patent No. 0165654 granted 1/27/93 Austria - AT 0165654 Belgium - BE 0165654 France - FR 0165654 Great Britain - GB 0165654 Germany Italy - IT 0165654 Luxembourg - LU 0165654 Netherlands - NL 0165654 Sweden - SE 0165654 Switzerland - P 0165654

T0050"288/9360

**SEC Filings**

Date Filed	Description	Form Type
2/16/99	Quarterly Data	<u>10-Q</u>
1/26/99	Proxy	<u>DEF 14A</u>
11/16/98	Quarterly Data	<u>10-Q</u>
9/28/98	Annual Data	<u>10-K</u>
5/15/98	Quarterly Data	<u>10-Q</u>
2/17/98	Quarterly Data	<u>10-Q</u>
12/1/97	Proxy	<u>DEF 14A</u>
11/19/97	Quarterly Data	<u>10-Q/A</u>
11/19/97	Preliminary Proxy	<u>PRE 14A</u>
11/13/97	Quarterly Data	<u>10-Q</u>
9/26/97	Annual Data	<u>10-K</u>
5/15/97	Quarterly Data	<u>10-Q</u>
2/13/97	Quarterly Data	<u>10-Q</u>
11/14/96	Quarterly Data	<u>10-Q</u>
10/1/96	Annual Data	<u>10-K</u>

T00E50"28829860



3rd Quarter (10 q) March 31, 1999

Balance Sheet

Statement of Operations

Statement of Cash Flows

Management Discussion and Analysis

CISTRON BIOTECHNOLOGY, INC.

BALANCE SHEETS

ASSETS	June 30, 1998	March 31, 1999
		(unaudited)
CURRENT ASSETS:		
Cash and equivalents	\$ 5,832,031	\$ 9,006,038
Accounts receivable-trade	101,859	66,972
Accounts receivable-other	2,940,673	2,903,931
Inventories	3,635	1,399
Taxes receivable	329,024	329,024
Notes receivable \$230,000; reserve \$230,000	-	-
TOTAL CURRENT ASSETS	9,207,222	12,307,364
ACCOUNTS RECEIVABLE - OTHER - Long Term	3,670,221	918,975
PROPERTY AND EQUIPMENT:		
Machinery and equipment	502,908	505,054
Furniture and fixtures	147,113	147,113
Leasehold improvements	77,674	77,674
	727,695	729,841
Less: Accumulated depreciation	701,477	705,363
	26,218	24,478
SECURITY DEPOSITS	23,938	23,938
PATENTS, Net of accumulated amortization of \$14,536 and \$16,523, respectively	22,569	20,582
DEFERRED TAXES	49,313	49,313
TOTAL ASSETS	\$ 12,999,481	\$ 13,344,650
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accrued expenses and accounts payable	\$ 114,894	\$ 85,373
Taxes payable	348,898	354,520
Other current liabilities	691,058	714,292
TOTAL CURRENT LIABILITIES	1,154,850	1,154,185
Other non-current liabilities	902,174	262,307
SHAREHOLDERS' EQUITY:		
Common stock, \$.01 par value; 50,000,000 shares authorized; issued and outstanding 26,930,187 shares and 28,263,520, respectively	269,302	282,635
Additional paid-in capital	8,683,680	9,600,347
Earnings accumulated during the development stage	2,384,125	2,439,826
Treasury stock 3,946,500 shares at cost	(394,650)	(394,650)

TOTAL SHAREHOLDERS' EQUITY	10,942,457	11,928,158
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 12,999,481	\$ 13,344,650

See accompanying notes to financial statements.

-3-

CISTRON BIOTECHNOLOGY, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months ended March 31, 1998	1999	February 2, 1982 (commencement of operations) to March 31, 1999
Sales.....	\$ 160,175	\$ 86,857	\$ 9,706,622
Cost of sales.....	86,484	38,395	4,311,242
Gross profit.....	73,691	48,462	5,395,380
Other income:			
Litigation settlements.....	-	-	14,684,206
License fees and funded research.....	5,000	783,000	4,963,899
Expenses:			
Research and development.....	92,863	119,495	8,818,483
Administrative and marketing.....	237,229	255,071	11,936,464
Occupancy.....	52,787	47,913	2,617,673
Total expenses.....	382,879	422,479	23,372,620
Operating income/(loss).....	(304,188)	408,983	1,670,865
Interest income/(expense) - net.....	149,177	88,310	1,171,178
Other expense.....	-	-	59,895
Amortization of deferred financing costs....	-	-	173,079
Acquisition expense.....	-	-	429,620
Income/(loss) before income taxes and extraordinary credit.....	(155,011)	497,293	2,179,449
Income tax provision (benefit).....	(82,973)	188,970	1,501,938
Income/(loss) before extraordinary credit...	(72,038)	308,323	677,511
Extraordinary credit - benefit of tax loss carryforward.....	-	-	262,838
Net income/(loss).....	\$ (72,038)	\$ 308,323	\$ 940,349
Net income/(loss) per share.....	\$ -	\$ 0.01	
Weighted average shares outstanding.....	22,983,687	24,317,020	
Net income/(loss) per share - assuming dilution.....	\$ -	\$ 0.01	
Weighted average shares outstanding - assuming dilution.....	22,983,687	25,859,394	

[Back to Top](#)

CISTRON BIOTECHNOLOGY, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

	Nine Months ended March 31, 1998	1999	February 2, 1982 (commencement of operations) to March 31, 1999
Sales.....	\$ 426,010	\$ 291,637	\$ 9,706,622
Cost of sales.....	234,244	193,913	4,311,242

Gross profit.....	191,766	97,724	5,395,380
Other revenues:			
Litigation settlement, net.....	-	-	14,684,206
License fee and funded research.....	205,000	852,750	4,963,899
Expenses:			
Research and development.....	462,770	275,137	8,818,483
Administrative and marketing.....	839,946	729,402	11,936,464
Occupancy.....	146,665	146,708	2,617,673
Total expenses.....	1,449,381	1,151,247	23,372,620
Operating income (loss).....	(1,052,615)	(200,773)	1,670,865
Interest income/(expense) - net.....	434,360	290,614	1,171,178
Other expense.....	-	-	59,895
Amortization of deferred financing costs....	-	-	173,079
Acquisition expense.....	-	-	429,620
Income (loss) before income taxes and extraordinary credit.....	(618,255)	89,841	2,179,449
Income tax provision (benefit).....	(234,937)	34,139	1,501,938
Income/(loss) before extraordinary credit...	(383,318)	55,702	677,511
Extraordinary credit - benefit of tax loss carryforward.....	-	-	262,838
Net income/(loss).....	\$ (383,318)	\$ 55,702	\$ 940,349
Net income/(loss) per share.....	\$ (0.01)	\$ -	
Weighted average shares outstanding.....	25,609,643	23,728,212	
Net income/(loss) per share - assuming dilution.....	\$ (0.01)	\$ -	
Weighted average shares outstanding - assuming dilution.....	25,609,643	26,647,226	

[Back to Top](#)

CISTRON BIOTECHNOLOGY, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months ended March 31, 1998	1999	February 2, 1982 (commencement of operations) to March 31, 1999
CASH FLOWS FROM OPERATING ACTIVITIES:			
Cash received from customers	\$ 394,462	\$ 333,425	\$ 11,588,119
Cash paid to suppliers and employees	(3,754,082)	(2,206,669)	(33,325,439)
Interest received	228,479	226,114	832,171
Acquisition expenses paid	-	-	(429,620)
Royalties, research funding, license fees received	205,000	889,605	3,567,592
Other receipts	3,002,207	3,003,678	18,141,226
Net cash provided by operating activities	76,066	2,246,153	374,049
CASH FLOWS FROM INVESTING ACTIVITIES:			
Collection of note receivable	-	-	15,097
Issuance of note receivable	-	-	(230,000)
Purchase of property and equipment	(3,926)	(2,146)	(764,618)
Net cash used in investing activities	(3,926)	(2,146)	(979,521)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from issuance of capital stock and additional contributions	2,879	930,000	10,876,398
Principal payments on notes payable	-	-	(870,238)
Purchase of treasury stock	(394,650)	-	(394,650)
Net cash provided by financing activities	(391,771)	930,000	9,611,510

Net change in cash and cash equivalents	(319,631)	3,174,007	9,006,038
CASH AND CASH EQUIVALENTS, beginning of period	6,368,228	5,832,031	-
CASH AND CASH EQUIVALENTS, end of period	\$ 6,048,597	\$ 9,006,038	\$ 9,006,038
RECONCILIATION OF NET INCOME (LOSS) TO NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES:			
Net income (loss)	\$ (383,318)	\$ 55,702	\$ 940,349
Adjustments to reconcile net income (loss) to net cash provided by operating activities:			
Depreciation and amortization	5,233	5,872	748,737
Issue of warrants	65,000	-	65,000
Deferred income taxes	(885,090)	-	(49,313)
Loss on disposal of property and equipment	4,552	-	8,531
Increase in reserve for note receivable	-	-	230,000
Amortization of deferred financing costs	-	-	195,179
Decrease (increase) in assets:			
Accounts receivable	(40,680)	34,887	(66,972)
Inventory	534	2,236	(1,399)
Taxes receivable	(8,525)	-	(329,024)
Notes and other receivables	2,728,680	2,787,988	(3,838,606)
Security deposit	-	-	(23,938)
Intangible assets	-	-	(37,105)
Increase (decrease) in liabilities:			
Accounts payable and accrued expenses	(798,412)	(23,899)	1,556,011
Other current and non-current liabilities	(611,908)	(616,633)	976,599
NET CASH PROVIDED BY OPERATING ACTIVITIES	\$ 76,066	\$ 2,246,153	\$ 374,049

[Back to Top](#)

Management's Discussion and Analysis of Results of Operations and Financial Condition

The following discussion should be read in conjunction with and is qualified in its entirety by the accompanying financial information and notes thereto, and management's discussion and analysis of results of operations and financial condition contained in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1998.

Certain statements in this discussion and analysis constitute forward-looking statements, are not historical facts, and involve risks and uncertainties that could cause actual results to differ from those expected and projected. Such risks and uncertainties include but are not limited to: (i) general economic conditions; (ii) conditions specific to the biotechnology industry; (iii) the Company's ability to develop or acquire new technology or products through licensing, merger or acquisition and to obtain regulatory approval to commercialize diagnostic or therapeutic products; (iv) the effectiveness and ultimate market acceptance of any such products; (v) limitations on third party reimbursements with respect to any such products; and (vi) competition. The Company does not undertake to update or revise any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

Results of Operations

The Company sells its products to the research market and has not generated significant revenues therefrom. The Company entered into an agreement with

RDS under which the Company granted RDS an exclusive license to produce and sell IL-1 antibodies and assays and a non-exclusive sublicense to manufacture and sell IL-1 protein to the research market. The agreement was reached in February 1999 and March was the last month in which the Company sold IL-1 research market products. The Company has retained all rights to therapeutic and diagnostic applications and will devote its efforts towards research and development in these areas. None of its products have been submitted to or received approval from the Food and Drug Administration for the sale of such products to the diagnostic or therapeutic markets.

The Company believes it is a development stage enterprise because planned principal operations have not yet commenced. The Company's planned principal operations include the development of clinical and therapeutic products for distribution through pharmaceutical and diagnostic companies. This requires the approval of the Company's products by the Food and Drug Administration ("FDA"). At March 31, 1999, none of the Company's products had received such approval. In addition, the Company continues to devote most of its efforts to activities such as research and development, financial planning and developing markets which are typical activities for a development stage enterprise. Specifically, the Company has expended funds relating to the antibody technology, wound healing and vaccine adjuvant programs. With respect to financial planning, from September 1997 to

September 1998, the Company engaged the services of BlueStone to act as Cistron's financial advisor as to corporate strategic and financial initiatives. In October 1998, the Company engaged Genome Securities, Inc. ("Genome"), to act in this capacity. In March 1999, the Company extended its engagement of Genome, under the same terms and conditions, through September 1999. Accordingly, as the Company has not yet commenced principal operations and is devoting most of its efforts to activities typical of a development stage enterprise as outlined in Statement of Financial Accounting Standards No.7, the Company believes that it continues to be in the development stage.

Three Months Ended March 31, 1999 and Three Months Ended March 31, 1998

Sales decreased \$73,318 (45.8%) in the quarter ended March 31, 1999 versus the same period of the prior year due to decreased sales of bulk cytokine assay kit components offset, in part, by increased sales of bulk cytokine proteins and cytokine assay kits. In February 1999, the Company reached agreement with RDS under which the Company granted RDS an exclusive license to produce and sell IL-1 antibodies and assays and a non-exclusive license to manufacture and sell IL-1 protein to the research market. March 1999 was the last month in which the Company sold IL-1 research market products. The Company has retained all rights to therapeutic and diagnostic applications and will devote its efforts towards research and development in these areas.

Cost of sales decreased \$48,089 (55.6%) from the prior year's quarter due to the lower sales volume and reclassification of some manufacturing personnel to the research department.

During the quarter ended March 31, 1999, the Company recorded \$69,750 of nonrefundable research funding under the collaboration agreement with PMC (\$75,000 net of fees due BlueStone Capital Partners) and \$713,250 of license fees from the agreement with RDS (\$750,000 net of fees due Genome). These amounts were recorded as other income in the quarter.

Operating expenses increased \$39,600 (10.3%) in the quarter ended March 31, 1999 versus the same quarter of the prior year. Research expenditures increased \$26,632 (28.7%) due to higher research salary expenditures as the result of reclassifying some manufacturing personnel to research and due to increased external research funding in the quarter versus last year's quarter.

Administrative and marketing expenses increased \$17,842 (7.5%) due to increased travel, audit and meeting expenses offset, in part, by lower salary expense. Occupancy expenses decreased \$4,874 (9.2%) due to lower utility expenses.

Interest income of \$86,810 was earned on the investment of higher cash balances. In addition, net interest income of \$1,500 was recognized on accounts receivable - other and other non-current liabilities to reflect the increase in their present value.

The Company had operating income of \$408,983 in the quarter largely as the result of an agreement with RDS and there can be no assurance that its operations will maintain profitability.

Nine Months Ended March 31, 1999 and Nine Months Ended March 31, 1998

Sales decreased \$134,373 (31.5%) in the nine-month period ended March 31,

1999 versus the same period of the prior year due to decreased sales of bulk cytokine assay kit components offset, in part, by increased sales of bulk cytokine proteins. In February 1999, the Company reached agreement with RDS under which the Company granted RDS an exclusive license to produce and sell IL-1 antibodies and assays and a non-exclusive license to manufacture and sell IL-1 protein to the research market. March 1999 was the last month in which the Company sold IL-1 research market products. The Company has retained all rights to therapeutic and diagnostic applications and will devote its efforts towards research and development in these areas.

Cost of sales decreased \$40,331 (17.2%) from the prior year's nine-month period due to the lower sales volume and reclassification of some manufacturing personnel to the research department.

During the nine months ended March 31, 1998, the Company received nonrefundable research and development of \$200,000, representing the last two of 10 consecutive quarterly payments of \$100,000 which another company had agreed to make to Cistron. In the nine months ended March 31, 1999, the Company received \$139,500 of non-refundable research payments (\$150,000) before fees due BlueStone Capital under the PMC agreement and \$713,250 of license fees (\$750,000 before fees due Genome) under the agreement with RDS. These amounts were recorded as other income in the nine-month period.

Operating expenses decreased \$298,134 (20.6%) in the nine months ended March 31, 1999 versus the same period of the prior year. Research expenses decreased \$187,633 (40.5%) due to lower research material and

consulting expenses and due to lower external research funding. The lower external research and consulting expenses are primarily due to spending in the prior year associated with preclinical periodontal disease studies.

Administrative and marketing expenses decreased \$110,544 (13.2%) due to lower salary, consulting, legal, and advertising and printing expenses offset, in part, by higher audit expenses. Occupancy expenses were unchanged.

Interest income of \$226,114 was earned on the investment of higher cash balances. In addition, \$64,500 was recognized on accounts receivable - other and other non-current liabilities to reflect the increase in their present value.

The Company had an operating loss of \$200,773 in the nine-month period ended March 31, 1999 and there can be no assurance that its operations will reach profitability.

Liquidity and Capital Resources

At March 31, 1999, the Company had current assets of \$12,307,364 including cash and cash equivalents of \$9,006,038 and had current liabilities of \$1,154,185. Cash used in the nine-month period ended March 31, 1999 was largely for operating expenses and payment of fees due the Institutions and attorneys on the receipt of funds by Cistron under a litigation settlement agreement and fees due BlueStone and Genome as the result of the equity investment and research payments made by PMC to Cistron and the agreement with RDS, respectively.

In September 1997, the Company engaged the services of BlueStone to act as Cistron's financial advisor as to corporate strategic and financial initiatives. The Company's agreement with BlueStone was not renewed at its expiration in September 1998. In October 1998, Cistron engaged Genome whose Chairman and CEO, Robert Naismith, Ph.D. is also a member of the Company's Board of Directors, to perform these services. In March 1999, the Company extended its engagement of Genome, under the same terms and conditions, through September 1999. In this regard, the Company has held exploratory discussions with several biotechnology and pharmaceutical companies regarding possible strategic alliances including joint ventures, mergers or the sale of the Company. There can be no assurance that any of these discussions will result in any agreements with the Company.

Management believes that it will have sufficient assets to fund the Company's current programs and plans through fiscal 1999 and beyond.

Year 2000 Impact

The Company's computers are stand-alone PC's running Microsoft Windows 95 programs. Microsoft believes these programs to be Year 2000 (Y2K) compatible. The volume of transactions processed via these programs can be handled manually, if need be, to prevent any interruptions in order processing. None of the manufacturing operations are dependent upon computer systems. Additionally, the Company has requested and will receive Y2K compliance statements from its major customers and suppliers. Those that have responded thus far have not indicated a Y2K problem. Currently, management does not foresee any negative impact from the Y2K event upon Cistron's business operations.

[Back to Top](#)



Corporate Information

Corporate Counsel

Epstein, Becker and Green
250 Park Avenue
New York, NY

Patent Counsel

Saliwanchik, Lloyd & Saliwanchik
Gainesville, FL

Independent Auditor

Deloitte & Touche LLP
Parsippany, New Jersey

Investor/Public Relations

Hal Smith Associates
Palm City, FL

1.00E50" 283/9850

- Financial Information
- 3rd Quarter Results
- Quote
- Historical Pricing
- Charts & Ratios
- Summary of Operations

Visit our future
site for online
trading



- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- **Public Exhibits**
 - SEC Filings
 - Exhibits
 - Press Release - 5/5/99
 - Press Release - 2/26/99
 - Press Release - 2/16/99
- [REDACTED]
- [REDACTED]
- [REDACTED]

Visit our future
site for online
trading



09867883.053001
T00250"28829850

- [REDACTED]
- [REDACTED]
- [REDACTED]
- **Therapeutic Potentials**
 - Why Inhibit IL-1
 - IL-1 β versus IL-1 α
 - Differences Between IL-1 α & IL-1 β
 - IL-1 β & Host Defense Mechanisms
 - Evidence that IL-1 β Mediates bone Resorption
 - Anti-cytokine-based Therapies
 - Future of Anti-Cytokine Therapies
 - Blocking IL-1 in RA
 - Multiple Myeloma
 - GVHD
 - Asthma
 - Role of IL-1 in Osteo
 - Other Possible Therapeutic Applications

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

Visit our future
site for online
trading



Research Experiments

- Antibody in Bioassay
- Antibody in Animals
- Antibody with Plasma
- With Human Cartilage
- IL-1 β -mab in Cartilage

Publications

- Anti Tumour Effects
- Biological Properties
- Effects of Treatment
- Treatment RA

Visit our future
site for online
trading



106650 2829860

Appendix B

5

Exemplary Web Statistics Summary Reports for June 24, 25, 26, and 28, 1999

according to a preferred embodiment of the present invention.

10




Yesterday

eMedTrade

General Statistics

The User Profile by Regions graph identifies the general location of the visitors to your Web site. The General Statistics table includes statistics on the total activity for this web site during the designated time frame.




General Statistics	
Date & Time This Report was Generated	Friday June 25, 1999 - 04:26:39
Timeframe	06/24/99 00:00:00 - 06/24/99 23:59:59
Number of Hits for Home Page	26
Number of Successful Hits for Entire Site	1,935
Number of Page Views (Impressions)	748
Number of User Sessions	81
User Sessions from United States	56.79%
International User Sessions	8.64%
User Sessions of Unknown Origin	34.56%
Average Number of Hits Per Day	1,935
Average Number of Page Views Per Day	748
Average Number of User Sessions Per Day	81
Average User Session Length	00:04:26

Number of Unique Users	53
Number of Users Who Visited Once	46
Number of Users Who Visited More Than Once	8

Most Requested Pages

This section identifies the most popular web site pages and how often they were accessed. The average time a user spends viewing a page is also indicated in the table.





Most Requested Pages					
	Pages	Views	% of Total Views	User Sessions	Avg. Time Viewed
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	92	12.29%	57	00:00:43
2	http://emedtrade.com/cistron/	57	7.62%	22	00:00:11
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	48	6.41%	44	00:00:36
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	45	6.01%	44	00:00:01
5	http://emedtrade.com/cistron/idxmain.htm	32	4.27%	21	00:00:19
6	http://emedtrade.com/cistron/idxcontents.htm	32	4.27%	21	00:00:11
7	EMedTrade.Com - Home Page http://emedtrade.com/	26	3.47%	21	00:04:01
8	http://emedtrade.com/cistron/company.htm	17	2.27%	12	00:00:04
9	http://emedtrade.com/cistron/companycontents.htm	17	2.27%	12	00:00:16
10	http://emedtrade.com/cistron/companytransactional.htm	17	2.27%	12	00:00:08
11	http://emedtrade.com/cfscript/processform.cfm	16	2.13%	13	00:01:46
12	http://emedtrade.com/cistron/revenue/Techne.htm	14	1.87%	12	00:00:28
13	http://emedtrade.com/cistron/intellectual/Protection.htm	14	1.87%	13	00:00:23

14	http://emedtrade.com/cistron/assessments/ProAssessments.htm	13	1.73%	11	00:00:10
15	http://emedtrade.com/cistron/intellectual.htm	13	1.73%	13	00:00:08
16	http://emedtrade.com/cistron/intellectualcontents.htm	13	1.73%	13	00:00:21
17	http://emedtrade.com/cistron/research/Pasture.htm	12	1.6%	10	00:00:17
18	http://emedtrade.com/cistron/assessments.htm	12	1.6%	10	00:00:01
19	http://emedtrade.com/cistron/assessmentscontents.htm	12	1.6%	10	00:00:07
20	http://emedtrade.com/cistron/revenuecontents.htm	11	1.47%	11	00:00:07
21	http://emedtrade.com/cistron/revenue.htm	11	1.47%	11	00:00:01
22	http://emedtrade.com/cistron/research.htm	11	1.47%	10	00:00:02
23	http://emedtrade.com/cistron/researchcontents.htm	11	1.47%	10	00:00:15
24	http://emedtrade.com/cistron/secfilings/cistronfilings.htm	11	1.47%	10	00:00:07
25	http://emedtrade.com/cistron/corporate.htm	10	1.33%	10	00:00:02
26	http://emedtrade.com/cistron/corporate/Corporate.htm	10	1.33%	9	00:00:02
27	http://emedtrade.com/cistron/company/management.htm	10	1.33%	8	00:00:22
28	http://emedtrade.com/cistron/filings.htm	10	1.33%	10	00:00:01
29	http://emedtrade.com/cistron/filingscontents.htm	10	1.33%	10	00:00:03
30	http://emedtrade.com/cistron/financial.htm	9	1.2%	8	
31	http://emedtrade.com/cistron/science/Science.htm	9	1.2%	8	00:00:14
32	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	9	1.2%	8	00:00:23
33	http://emedtrade.com/cistron/financialcontents.htm	9	1.2%	8	00:00:03
34	http://emedtrade.com/cistron/corporatecontents.htm	9	1.2%	9	00:00:08
35	http://emedtrade.com/cistron/science.htm	8	1.06%	8	00:00:01
36	http://emedtrade.com/cistron/sciencecontents.htm	8	1.06%	8	00:00:01
37	http://emedtrade.com/cistron/intellectual/Licenses.htm	7	0.93%	7	00:00:22
38	http://emedtrade.com/cistron/company/busoverview.htm	6	0.8%	6	00:01:01
39	http://emedtrade.com/cistron/company/employees.htm	6	0.8%	6	00:00:13
40	http://emedtrade.com/cistron/intellectual/USPatents.htm	6	0.8%	5	00:00:46
Sub Total For the Page Views Above		693	92.64%	N/A	N/A
Total For the Log File		748	100%	N/A	N/A

Least Requested Pages

This section identifies the least popular pages on your Web site, and how often they were accessed.





DrRosenwasser.htm

GVHD.htm


other1.htm

Least Requested Pages

	Pages	Views	% of Total Views	User Sessions
1	http://emedtrade.com/cistron/secfilings/recent2.htm	1	0.13%	1
2	http://emedtrade.com/cistron/secfilings/recent1.htm	1	0.13%	1
3	http://emedtrade.com/cistron/assessments/DrRosenwasser.htm	1	0.13%	1
4	http://emedtrade.com/cistron/assessments/GVHD.htm	1	0.13%	1
5	http://emedtrade.com/cistron/assessments/other1.htm	1	0.13%	1
6	http://emedtrade.com/cistron/science/IC8-bioassay.htm	1	0.13%	1
7	http://emedtrade.com/cistron/science/NeutralizationStudy1.htm	1	0.13%	1
8	http://emedtrade.com/cistron/science/IC8-bioassay1.htm	1	0.13%	1
9	http://emedtrade.com/cistron/secfilings/recent.htm	1	0.13%	1
10	http://emedtrade.com/cistron/assessments/versus.htm	2	0.26%	2
11	http://emedtrade.com/cistron/secfilings/exhibits.htm	2	0.26%	2
12	http://emedtrade.com/cistron/financials/Sumofops.htm	2	0.26%	2
13	http://emedtrade.com/cistron/financials/historical.htm	2	0.26%	2
14	http://emedtrade.com/cistron/science/Research/Antitumoureffects.htm	2	0.26%	2
15	http://emedtrade.com/cistron/science/IL-1B-mab1.htm	2	0.26%	2
16	http://emedtrade.com/cistron/science/Regulation-of-Nitric-Oxide.htm	2	0.26%	2
17	http://emedtrade.com/cistron/assessments/DrLust.htm	2	0.26%	2
18	http://emedtrade.com/cistron/science/Research/rheumatoid.htm	2	0.26%	2
19	http://emedtrade.com/cistron/science/Research/effectsoftreatment.htm	2	0.26%	2
20	http://emedtrade.com/cistron/science/Research/biologicalproperties.htm	2	0.26%	2
21	http://emedtrade.com/cistron/assessments/DrAmin.htm	3	0.4%	3
22	http://emedtrade.com/cistron/assessments/DrDinareello.htm	3	0.4%	3
23	http://emedtrade.com/cistron/intellectual/ForeignPatents.htm	4	0.53%	4
24	http://emedtrade.com/cistron/assessments/other.htm	4	0.53%	4
25	http://emedtrade.com/cistron/assessments/Arthritis.htm	5	0.66%	3
26	http://emedtrade.com/cistron/financials/ratio.htm	5	0.66%	4
27	http://emedtrade.com/cistron/intellectual/USPatents.htm	6	0.8%	5
28	http://emedtrade.com/cistron/company/employees.htm	6	0.8%	6
29	http://emedtrade.com/cistron/company/busoverview.htm	6	0.8%	6
30	http://emedtrade.com/cistron/intellectual/Licenses.htm	7	0.93%	7

Top Entry Pages

This section identifies the first page viewed when a user visits this site. This is most likely your home page but, in some cases, it may also be specific URLs that users enter to access a particular page directly. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not be counted as an Entry Page, and the session is not counted in the total.




Top Entry Pages			
	File	% of Total	User Sessions
1	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	53.42%	39
2	EMedTrade.Com - Home Page http://emedtrade.com/	17.8%	13
3	http://emedtrade.com/cistron/	16.43%	12
4	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	4.1%	3
5	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	1.36%	1
6	http://emedtrade.com/cistron/financial.htm	1.36%	1
7	http://emedtrade.com/cistron/assessments.htm	1.36%	1
8	http://emedtrade.com/cistron/company.htm	1.36%	1
9	http://emedtrade.com/Cistron/financials/ratio.htm	1.36%	1
10	http://emedtrade.com/cistron/assessments/ProAssessments.htm	1.36%	1
	Total For the Pages Above	100%	73

Top Exit Pages

This section identifies the pages users were on when they left the site. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a

different type (such as a graphic or sound file), the file is not counted as an Exit Page, and the session is not counted in the total.




Top Exit Pages			
	Pages	% of Total	User Sessions
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	38.35%	28
2	EMedTrade.Com - Home Page http://emedtrade.com/	19.17%	14
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	10.95%	8
4	http://emedtrade.com/cfscrip/processform.cfm	5.47%	4
5	http://emedtrade.com/cistron/idxcontents.htm	4.1%	3
6	http://emedtrade.com/cistron/idxmain.htm	4.1%	3
7	http://emedtrade.com/cistron/intellectualcontents.htm	2.73%	2
8	http://emedtrade.com/cistron/company/management.htm	1.36%	1
9	http://emedtrade.com/cistron/secfilings/cistronfilings.htm	1.36%	1
10	http://emedtrade.com/cistron/assessments/other.htm	1.36%	1
11	http://emedtrade.com/cistron/corporate/Corporate.htm	1.36%	1
12	http://emedtrade.com/cistron/filingscontents.htm	1.36%	1
13	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	1.36%	1
14	http://emedtrade.com/cistron/companycontents.htm	1.36%	1
15	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	1.36%	1
Total For the Pages Above (only sessions starting on a valid document type are included)		95.89%	70

Single Access Pages

This section identifies the pages on the site that visitors access and exit without viewing any other page. The


percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as a Single Access Page, and the session is not counted in the total




Single Access Pages			
	Pages	% of Total	User Sessions
1	EMedTrade.Com - Home Page http://emedtrade.com/	64.28%	9
2	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	14.28%	2
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	7.14%	1
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	7.14%	1
5	http://emedtrade.com/cistron/assessments/ProAssessments.htm	7.14%	1
	Total For the Pages Above	100%	14

Most Downloaded File Types

This section identifies the accessed file types and the total kilobytes downloaded for each file type. Cached requests and erred hits are excluded from the totals.






Most Downloaded File Types

	File type	Files	K Bytes Transferred
1	htm	732	2,350
2	GIF	633	2,398
3	jpg	86	967
4	cfm	16	23
Total Files & K Bytes Transferred		1,467	5,737

Most Active Countries

This section identifies the top locations of the visitors to the site by country. The country of the user is determined by the suffix of their domain name. Use this information carefully because this information is based on where the domain name of the visitor is registered, and may not always be an accurate identifier of the actual geographic location of this visitor. For example, while a vast majority of .com domain names are from the United States, there is a small minority of domain names that exist outside of the United States.


Most Active Countries



Most Active Countries		
	Countries	User Sessions
1	United States	46
2	UK	5
3	Switzerland	1
4	Czech Republic	1
	Total	53

North American States and Provinces


This section breaks down web site activity to show which of the North American States and Provinces were the most active on the site. This information is based on where the domain name of the visitor is registered, and may not always be an accurate representation of the actual geographic location of this visitor. This information can only be displayed if reverse DNS lookups have been performed.



North American States & Provinces		
	State	User Sessions
1	Virginia	8
2	California	7
3	Utah	4
4	Illinois	1
5	Washington	1
6	Pennsylvania	1
7	South Carolina	1
	Total For the States Above	23

Most Active Organizations

This section identifies the companies or organizations that accessed the site the most often.




Most Active Organizations				
	Organizations	Hits	% of Total Hits	User Sessions
1	Corixa Corp. corixa.com	303	15.65%	1
2	209.146.61.155	221	11.42%	2
3	209.227.18.200	192	9.92%	2
4	mrc.ac.uk	176	9.09%	3
5	208.169.102.230	145	7.49%	14
6	Myriad Genetics myriad.com	141	7.28%	4
7	204.57.233.144	120	6.2%	2
8	mobilenetics.com	110	5.68%	4
9	voicenet.com	98	5.06%	1
10	superlink.net	74	3.82%	3
11	flashcom.net	70	3.61%	1
12	Uunet Technologies Inc. uu.net	67	3.46%	4
13	DEFAULT	21	1.08%	1
14	chiron.com	12	0.62%	2
15	Netcom Online Services netcom.com	12	0.62%	2
16	203.197.56.32	11	0.56%	1
17	MEGABIOS megabios.com	8	0.41%	1
18	intiques.net	7	0.36%	2

19	hepavec.com	6	0.31%	1
20	195.33.192.34	6	0.31%	1
Sub Total For Companies Above		1,800	93.02%	52
Total For the Log File		1,935	100%	81

Organization Breakdown


This section provides a breakdown by types of organizations (.com, .net, .edu, .org, .mil, and .gov.) This information can only be displayed if reverse DNS lookups have been performed, and the percentages refer to the total of hits for which the organization type can be determined (some IPs cannot be resolved to a domain, and therefore an organization type cannot be determined).



Organization Breakdown				
	Organization Type	Hits	% of Total Hits	User Sessions
1	Company	778	65.7%	36
2	Network	230	19.42%	12
3	Education	176	14.86%	3
	Total for Known Organization Types	1,184	100%	51


Summary of Activity by Time Increment

This section helps you understand the bandwidth requirements of the site by indicating the volume of activity in kilobytes transferred. The table provides various measures of activity by unit of time for the report period (the unit of time depends on the amount of time covered by the report, and will be the day in most cases).



Activity Level by Day of the Week

This section shows the activity for each day of the week for the report period (i.e. if there are two Mondays in the report period, the value presented is the sum of all hits for both Mondays.) Values in the table do not include erred hits.




Activity Level by Day of the Week				
	Day	Hits	% of Total Hits	User Sessions
1	Sun	0	0%	0
2	Mon	0	0%	0
3	Tue	0	0%	0
4	Wed	0	0%	0

5	Thu	1,935	100%	81
6	Fri	0	0%	0
7	Sat	0	0%	0
Total Weekdays		1,935	100%	81
Total Weekend		0	0	0

Activity Level by Hour of the Day

This section shows the most and the least active hour of the day for the report period. The second table breaks down activity for the given report period to show the average activity for each individual hour of the day (if there are several days in the report period, the value presented is the sum of all hits during that period of time for all days). All times are referenced to the location of the system running the analysis.




Activity Level by Hours Details			
Hour	# of Hits	% of Total Hits	# of User Sessions
00:00-00:59	1	0.05%	1
01:00-01:59	13	0.67%	3
02:00-02:59	6	0.31%	1
03:00-03:59	0	0%	0
04:00-04:59	0	0%	0
05:00-05:59	6	0.31%	1
06:00-06:59	96	4.96%	3
07:00-07:59	14	0.72%	6
08:00-08:59	3	0.15%	2
09:00-09:59	31	1.6%	5
10:00-10:59	137	7.08%	6
11:00-11:59	302	15.6%	10
12:00-12:59	572	29.56%	8

13:00-13:59	235	12.14%	6
14:00-14:59	129	6.66%	7
15:00-15:59	188	9.71%	5
16:00-16:59	19	0.98%	4
17:00-17:59	93	4.8%	3
18:00-18:59	26	1.34%	4
19:00-19:59	15	0.77%	3
20:00-20:59	6	0.31%	1
21:00-21:59	1	0.05%	1
22:00-22:59	0	0%	0
23:00-23:59	42	2.17%	1
Total Users during Work Hours (8:00am-5:00pm)	1,616	83.51%	53
Total Users during After Hours (5:01pm-7:59am)	319	16.48%	28

Top Referring Sites


This section identifies the domain names or numeric IP addresses with links to the site. This information will only be displayed if your server is logging this information.



Top Referring Sites		
	Site	User Sessions
1	http://www.genomesecurities.com/	43
2	No Referrer	20
3	http://www.emedtrade.com/	10
4	http://www.genomesecurities.com/	7
5	http://www.biospace.com/	1
Sub Total for the Referring Sites Above		81
Total for the Log File		81

Top Referring URLs


This section provides the full URLs of the sites with links to the site. This information will only be displayed if your server is logging the referrer information.



Top Referring URLs		
	URL	User Sessions
1	http://www.genomesecurities.com/	33
2	No Referrer	20
3	http://www.genomesecurities.com./	7
4	http://www.genomesecurities.com/index.html	5
5	http://www.emedtrade.com/	3
6	http://www.genomesecurities.com/Transactions/transactions.html	2
7	http://www.genomesecurities.com/Mandates/mandates.html	1
8	http://www.genomesecurities.com/Advisory Board/Cohen/cohen.html	1
9	http://www.emedtrade.com/cistron	1
10	http://www.biospace.com/b2/news.cfm	1
11	http://www.emedtrade.com/cistron/filingscontents.htm	1
12	http://www.emedtrade.com/cistron/	1
13	http://www.emedtrade.com/cistron/idxcontents.htm	1
14	http://www.genomesecurities.com/Contact Us/contact_us.html	1
15	http://www.emedtrade.com/cistron/intellectualcontents.htm	1
16	http://www.emedtrade.com/Cistron/financialcontents.htm	1
17	http://www.emedtrade.com/_private/stats/yesterday_01_b.html	1
Sub Total for the Referrers Above		81
Total for the Log File		81

Most Used Browsers

This section identifies the most popular WWW Browsers used by visitors to the site. This information will only be displayed if your server is logging the browser/platform information.



Most Used Browsers				
	Browser	Hits	% of Total Hits	User Sessions
1	Microsoft Internet Explorer	1,453	75.09%	39
2	Netscape	465	24.03%	31
3	Other Netscape Compatible	8	0.41%	5
4	MSPProxy/2.0	8	0.41%	5
5	Lotus-Notes/4.5 (Windows-NT)	1	0.05%	1
	Total For Browsers Above	1,935	100%	81

Glossary

Glossary	
Ad Clicks	A click on an advertisement on a web site which takes a user to another site, it is referred to as an ad click.
Ad Views	A web page that presents an ad. Once the visitor has viewed an ad, he/she can click on it (see Ad Click). There may be more than one ad on an ad view.
Authentication	Technique by which access to Internet or Intranet resources requires the user to identify himself or herself by entering a username and password.
Bandwidth	Measure (in kilobytes of data transferred) of the traffic on the site.
Browser	A program used to locate and view HTML documents (Netscape, Mosaic, Microsoft Explorer, for example.)
Click through rate	Percentage of users who click on a viewed advertisement. This is a good indication of the effectiveness of this ad.

Client	The browser (see above) used by a visitor to a Web site.
Client Errors	An error occurring due to an invalid request by the visitor's browser. Client errors are in the 400-range. See "Return Code" definition.
Company Database	The database installed and used by WebTrends to look up the company name, city, state and country corresponding to a specific domain name.
Cookies	Persistent Client-State HTTP Cookies are files containing information about visitors to a web site (e.g., user name and preferences). This information is provided by the user during the first visit to a Web server. The server records this information in a text file and stores this file on the visitor's hard drive. When the visitor accesses the same web site again, the server looks for the cookie and configures itself based on the information provided.
Domain Name	The text name corresponding to the numeric IP address of a computer on the Internet (i.e., www.webtrends.com).
Domain Name Lookup	The process of converting a numeric IP address into a text name (for example, 204.245.240.194 is converted to www.webtrends.com).
FTP	File Transfer Protocol is a standard method of sending files between computers over the Internet.
Filters	A means of narrowing the scope of a report or view by specifying ranges or types of data to include in or exclude.
Forms	An HTML page which passes variables back to the server. These pages are used to gather information from users. Also referred to as scripts.
GIF	Graphics Interchange Format is an image file format commonly used in HTML documents.
HTML	Hyper Text Markup Language is used to write documents for the World Wide Web to specify hypertext links between related objects and documents.
HTTP	Hyper Text Transfer Protocol is a standard method of transferring data between a Web server and a Web browser.
Hit	An action on the Web site, such as when a user views a page or downloads a file.
Home Page	The main page of a Web site. The home page provides visitors with an overview and links to the rest of the site. It often contains or links to a Table of contents for the site.
Home Page URL	The local path or Internet URL to the default page of the Web site for which WebTrends reports will be generated.
IP Address	Internet Protocol address identifying a computer connected to the Internet.
Log File	A file created by a web or proxy server which contains all of the access information regarding the activity on that server.
Page Views	Also called Page Impressions. Hit to HTML pages only (access to non-HTML documents are not counted).
Platform	The operating system (i.e. Windows 95, Windows NT, etc.) used by a visitor to the site.
Protocol	An established method of exchanging data over the Internet.
Referrer	URL of an HTML page that refers to the site.
Return Code	<p>The return status of the request which specifies whether the transfer was successful and why.</p> <p>Possible "Success" codes are:</p> <ul style="list-style-type: none"> 200 = Success: OK 201 = Success: Created 202 = Success: Accepted 203 = Success: Partial Information 204 = Success: No Response 300 = Success: Redirected 301 = Success: Moved 302 = Success: Found

	<p>303 = Success: New Method 304 = Success: Not Modified Possible "Failed" codes are: 400 = Failed: Bad Request 401 = Failed: Unauthorized 402 = Failed: Payment Required 403 = Failed: Forbidden 404 = Failed: Not Found 500 = Failed: Internal Error 501 = Failed: Not Implemented 502 = Failed: Overloaded Temporarily 503 = Failed: Gateway Timeout</p>
Server	A computer that hosts information available to anyone accessing the Internet.
Server Error	An error occurring at the server. Web server errors have codes in the 500 range.
Spiders	An automated program which searches the internet.
Suffix (Domain Name)	<p>The three digit suffix of a domain can be used to identify the type of organization.</p> <p>Possible "Suffixes" are:</p> <ul style="list-style-type: none"> .com = Commercial .edu = Educational .int = International .gov = Government .mil = Military .net = Network .org = Organization
URL	Uniform Resource Locator is a means of identifying an exact location on the Internet. For example, http://www.webtrends.com/html/info/default.htm is the URL which defines the use of HTTP to access the Web page Default.htm in the /html/info/ directory on the WebTrends Corporation Web site. As the previous example shows, a URL is comprised of four parts: Protocol Type (HTTP), Machine Name (webtrends.com), Directory Path (/html/info/), and File Name (default.htm).
User Agent	Fields in an extended Web server log file identifying the browser and platform used by a visitor.
User Session	A session of activity (all hits) for one user of a web site. A unique user is determined by the IP address or cookie. By default, a user session is terminated when a user is inactive for more than 30 minutes. This duration can be changed from General panel in the Options, Web Log Analysis dialog. Synonym: Visit.
View,Page	Each request for a particular web page which displays an ad. Also referred to as an impression.
Visit	Commonly called User Session. All activity for one user of a web site. By default, a user session is terminated when a user is inactive for more than 30 minutes.



This report was generated by WebTrends.

WebTrends is a registered trademark and CommerceTrends is a trademark of WebTrends Corporation. Other trademarks are the property of their respective owners.

☐ General Statistics

General Statistics

☐ Resources Accessed

Most Requested Pages

Least Requested Pages

Top Entry Pages

Top Exit Pages

Single Access Pages

Most Downloaded File Types

☐ Visitors & Demographics

Most Active Countries

North American States

Most Active Organizations

Organization Breakdown

☐ Activity Statistics

Summary of Activity by Time Increment

Activity Level by Day of the Week

Activity Level by Hour

☐ Referrers & Keywords

Top Referring Sites

Top Referring URLs

☐ Browsers & Platforms

Most Used Browsers

☐ Glossary

Glossary

TODAY: 233/2960




Yesterday

eMedTrade

General Statistics

The User Profile by Regions graph identifies the general location of the visitors to your Web site. The General Statistics table includes statistics on the total activity for this web site during the designated time frame.

User Profile by Regions



General Statistics

Date & Time This Report was Generated	Thursday June 24, 1999 - 19:10:53
Timeframe	06/23/99 00:00:00 - 06/23/99 23:59:59
Number of Hits for Home Page	14
Number of Successful Hits for Entire Site	1,836
Number of Page Views (Impressions)	659
Number of User Sessions	120
User Sessions from United States	75.83%
International User Sessions	4.16%
User Sessions of Unknown Origin	20%
Average Number of Hits Per Day	1,836
Average Number of Page Views Per Day	659
Average Number of User Sessions Per Day	120
Average User Session Length	00:06:18 <i>Excellent</i>


Number of Unique Users	99
Number of Users Who Visited Once	87
Number of Users Who Visited More Than Once	12

- you
me
QAN

VG → (89)

Most Requested Pages

This section identifies the most popular web site pages and how often they were accessed. The average time a user spends viewing a page is also indicated in the table.



Most Requested Pages					
	Pages	Views	% of Total Views	User Sessions	Avg. Time Viewed
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	95	14.41%	56	00:00:51
2	http://emedtrade.com/cistron/	55	8.34%	26	00:00:28
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	49	7.43%	47	00:00:58
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	48	7.28%	46	00:00:24
5	http://emedtrade.com/cistron/idxcontents.htm	32	4.85%	22	00:00:37
6	http://emedtrade.com/cistron/idxmain.htm	31	4.7%	22	00:00:48
7	http://emedtrade.com/cfscript/processform.cfm	24	3.64%	17	00:03:22
8	http://emedtrade.com/cistron/assessmentscontents.htm	24	3.64%	8	00:00:16
9	http://emedtrade.com/cistron/assessments.htm	21	3.18%	8	00:00:03
10	http://emedtrade.com/cistron/assessments/ProAssessments.htm	21	3.18%	8	00:00:55
11	EMedTrade.Com - Home Page http://emedtrade.com/	14	2.12%	13	00:02:41
12	http://emedtrade.com/cistron/company/transactionrational.htm	13	1.97%	12	00:00:41
13	http://emedtrade.com/cistron/companycontents.htm	13	1.97%	12	00:00:06

VG

VG
VG

01:00 03:00 05:00 07:00 09:00
00:00:00 - 23:59:59 (1 Day Scale)

■ IL-1B-6201.170

Least Requested Pages


	Pages	Views	% of Total Views	User Sessions
1	http://emedtrade.com/cistron/science/Regulation-of-Nitric-Oxide.htm	1	0.15%	1
2	http://emedtrade.com/cistron/science/NeutralizationStudy1.htm	1	0.15%	1
3	http://emedtrade.com/cistron/assessments/DrRosenwasser.htm	1	0.15%	1
4	http://emedtrade.com/cistron/assessments/GVHD.htm	1	0.15%	1
5	http://emedtrade.com/cistron/science/IL-1B-mab1.htm	1	0.15%	1
6	http://emedtrade.com/cistron/filings.htm	2	0.3%	2
7	http://emedtrade.com/cistron/assessments/Arthritis.htm	2	0.3%	2
8	http://emedtrade.com/cistron/assessments/other.htm	2	0.3%	2
9	http://emedtrade.com/cistron/intellectual/ForeignPatents.htm	2	0.3%	2
10	http://emedtrade.com/cistron/secfilings/recent.htm	2	0.3%	2
11	http://emedtrade.com/cistron/financials/Sumofops.htm	2	0.3%	2
12	http://emedtrade.com/cistron/science/IC8-bioassay1.htm	2	0.3%	2
13	http://emedtrade.com/cistron/intellectual/Licenses.htm	2	0.3%	2
14	http://emedtrade.com/cistron/secfilings/cistronfilings.htm	2	0.3%	2
15	http://emedtrade.com/cistron/assessments/DrLust.htm	2	0.3%	2
16	http://emedtrade.com/cistron/science/Research/rheumatoid.htm	2	0.3%	2
17	http://emedtrade.com/cistron/science/Research/effectsoftreatment.htm	2	0.3%	2
18	http://emedtrade.com/cistron/science/Research/biologicalproperties.htm	2	0.3%	2
19	http://emedtrade.com/cistron/science/Research/Antitumoureffects.htm	2	0.3%	2
20	http://emedtrade.com/cistron/filingscontents.htm	2	0.3%	2
21	http://emedtrade.com/cistron/intellectual/USPatents.htm	3	0.45%	3
22	http://emedtrade.com/cistron/financials/historical.htm	3	0.45%	3
23	http://emedtrade.com/cistron/researchcontents.htm	3	0.45%	3
24	http://emedtrade.com/cistron/research/Pasteur.htm	3	0.45%	3
25	http://emedtrade.com/cistron/research.htm	3	0.45%	3
26	http://emedtrade.com/cistron/financials/ratio.htm	4	0.6%	4
27	http://emedtrade.com/cistron/corporate/Corporate.htm	4	0.6%	4
28	http://emedtrade.com/cistron/corporatecontents.htm	4	0.6%	4
29	http://emedtrade.com/cistron/corporate.htm	4	0.6%	4
30	http://emedtrade.com/cistron/assessments/DrDinarello.htm	4	0.6%	4

R.
Donck
Pg.

Top Entry Pages

This section identifies the first page viewed when a user visits this site. This is most likely your home page but, in some cases, it may also be specific URLs that users enter to access a particular page directly. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not be counted as an Entry Page, and the session is not counted in the total.

Top Entry Pages



Top Entry Pages

	File	% of Total	User Sessions
1	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	42.85%	42
2	http://emedtrade.com/cistron/	15.3%	15
3	EMedTrade.Com - Home Page http://emedtrade.com/	10.2%	10
4	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	9.18%	9
5	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	4.08%	4
6	http://emedtrade.com/cistron/idxcontents.htm	3.06%	3
7	http://emedtrade.com/cistron/company.htm	2.04%	2
8	http://emedtrade.com/cistron/company/transactionrational.htm	2.04%	2
9	http://emedtrade.com/cistron/financialcontents.htm	2.04%	2
10	http://emedtrade.com/cfscript/processform.cfm	2.04%	2
11	http://emedtrade.com/cistron/intellectual/Protection.htm	1.02%	1
12	http://emedtrade.com/cistron/sciencecontents.htm	1.02%	1
13	http://emedtrade.com/cistron/assessments/DrDinarelo.htm	1.02%	1
14	http://emedtrade.com/cistron/company/employees.htm	1.02%	1
15	http://emedtrade.com/cistron/corporate.htm	1.02%	1
16	http://emedtrade.com/cistron/corporatecontents.htm	1.02%	1
17	http://emedtrade.com/cistron/financials/ratio.htm	1.02%	1
	Total For the Pages Above	100%	98

Top Exit Pages


This section identifies the pages users were on when they left the site. The percentages refer to the total

http://www.emedtrade.com/_private/stats/yesterday_01_b.html

6/24/99

09867882-0501

number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as an Exit Page, and the session is not counted in the total.



Top Exit Pages			
	Pages	% of Total	User Sessions
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	23.95%	23
2	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	9.37%	9
3	EMedTrade.Com - Home Page http://emedtrade.com/	8.33%	8
4	http://emedtrade.com/cfscrip/processform.cfm	7.29%	7
5	http://emedtrade.com/cistron/idxcontents.htm	4.16%	4
6	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	3.12%	3
7	http://emedtrade.com/cistron/financialcontents.htm	3.12%	3
8	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	3.12%	3
9	http://emedtrade.com/cistron/	3.12%	3
10	http://emedtrade.com/cistron/intellectualcontents.htm	2.08%	2
11	http://emedtrade.com/cistron/intellectual/Protection.htm	2.08%	2
12	http://emedtrade.com/cistron/financial.htm	2.08%	2
13	http://emedtrade.com/cistron/companycontents.htm	2.08%	2
14	http://emedtrade.com/cistron/company.htm	2.08%	2
15	http://emedtrade.com/cistron/corporate/Corporate.htm	2.08%	2
	Total For the Pages Above (only sessions starting on a valid document type are included)	78.12%	75

People went there but didn't stay in


Single Access Pages

http://www.emedtrade.com/_private/stats/yesterday_01_b.html

6/24/99

T00350"2829860

This section identifies the pages on the site that visitors access and exit without viewing any other page. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as a Single Access Page, and the session is not counted in the total




Single Access Pages			
	Pages	% of Total	User Sessions
1	EMedTrade.Com - Home Page http://emedtrade.com/	25%	7
2	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	14.28%	4
3	http://emedtrade.com/cistron/company.htm	7.14%	2
4	http://emedtrade.com/cistron/financialcontents.htm	7.14%	2
5	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	7.14%	2
6	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	7.14%	2
7	http://emedtrade.com/cistron/idxcontents.htm	7.14%	2
8	http://emedtrade.com/cistron/	7.14%	2
9	http://emedtrade.com/cistron/intellectual/Protection.htm	3.57%	1
10	http://emedtrade.com/cistron/sciencecontents.htm	3.57%	1
	Total For the Pages Above	89.28%	25

Most Downloaded File Types

This section identifies the accessed file types and the total kilobytes downloaded for each file type. Cached requests and erred hits are excluded from the totals.

Most Downloaded File Types




Most Downloaded File Types

	File type	Files	K Bytes Transferred
1	gif	673	2,002
2	htm	635	2,087
3	jpg	78	915
4	cfm	24	34
Total Files & K Bytes Transferred		1,410	5,037

Dynamic Pages & Forms

This section identifies the most popular dynamic pages and forms executed by the server. WebTrends counts any line with a Post command or a Get command with a "?" as a dynamic page, and shows only successful hits.


Dynamic Pages & Forms



Dynamic Pages & Forms			
	Dynamic Pages	No. of Pages	% of Total User Sessions
1	http://emedtrade.com/cfscrip/processform.cfm	24	100%

Most Active Countries

This section identifies the top locations of the visitors to the site by country. The country of the user is determined by the suffix of their domain name. Use this information carefully because this information is based on where the domain name of the visitor is registered, and may not always be an accurate identifier of the actual geographic location of this visitor. For example, while a vast majority of .com domain names are from the United States, there is a small minority of domain names that exist outside of the United States.




Most Active Countries		
	Countries	User Sessions
1	United States	91
2	Switzerland	2
3	UK	1
4	Italy	1
5	Australia	1
	Total	96

North American States and Provinces

This section breaks down web site activity to show which of the North American States and Provinces were the most active on the site. This information is based on where the domain name of the visitor is registered,


and may not always be an accurate representation of the actual geographic location of this visitor. This information can only be displayed if reverse DNS lookups have been performed.




North American States & Provinces		
	State	User Sessions
1	Virginia	58
2	Massachusetts	2
3	Washington	2
4	California	2
5	Michigan	1
6	Wisconsin	1
7	New Jersey	1
8	Arizona	1
9	New York	1
10	Illinois	1
	Total For the States Above	70

Most Active Organizations

This section identifies the companies or organizations that accessed the site the most often.





- 3. 209.146.61.155
- 6. 208.246.201.71
- 7. ns.ibo.ch
- 8. 206.129.54.2
- 9. att.net
- 10. ultra.net

Most Active Organizations

	Organizations	Hits	% of Total Hits	User Sessions
1	intiques.net	393	21.4%	3
2	208.169.102.230	260	14.16%	11
3	America Online aol.com	173	9.42%	55
4	antexbio.com	167	9.09%	1
5	209.146.61.155	122	6.64%	5
6	208.246.201.71	87	4.73%	1
7	ns.ibo.ch	78	4.24%	2
8	206.129.54.2	69	3.75%	1
9	At&T Easylink Services att.net	67	3.64%	1
10	Ultraset Communications Inc. ultra.net	52	2.83%	1
11	Penteledata Inc. ptd.net	47	2.55%	1
12	comcastatwork.com	45	2.45%	1
13	mitokor.com	45	2.45%	1
14	206.129.56.1	20	1.08%	1
15	Unet Technologies Inc. uu.net	17	0.92%	3
16	207.78.88.202	12	0.65%	1
17	Immunex Corp. immunex.com	12	0.65%	2
18	superlink.net	11	0.59%	2
19	W-AWONG	10	0.54%	2
20	207.228.164.194	10	0.54%	1
	Subtotal For Companies Above	1,697	92.42%	96
	Total For the Log File	1,836	100%	120

ME-
CHAM


~~ME-
CHAM~~

Interestr

Organization Breakdown

This section provides a breakdown by types of organizations (.com, .net, .edu, .org, .mil, and .gov.) This information can only be displayed if reverse DNS lookups have been performed, and the percentages refer to the total of hits for which the organization type can be determined (some IPs cannot be resolved to a domain, and therefore an organization type cannot be determined).

Organization Breakdown



Organization Breakdown

	Organization Type	Hits	% of Total Hits	User Sessions
1	Network	602	52.25%	14
2	Company	540	46.87%	77
3	Education	10	0.86%	1
	Total for Known Organization Types	1,152	100%	92

Summary of Activity for Report Period

This section outlines general server activity, comparing the level of activity on weekdays and weekends. The Average Number of Users and Hits on Weekdays are the averages for each individual week day. The Average Number of Users and Hits for Weekends groups Saturday and Sunday together. Values in the table do not include erred hits.


Summary of Activity for Report Period

Average Number of <i>Users</i> per day on Weekdays	120
Average Number of <i>Hits</i> per day on Weekdays	1,836
Average Number of <i>Users</i> for the entire Weekend	0
Average Number of <i>Hits</i> for the entire Weekend	0
Most Active Day of the Week	Wed
Least Active Day of the Week	Sun
Most Active Day Ever	June 23, 1999
Number of Hits on Most Active Day	1,836
Least Active Day Ever	June 23, 1999
Number of Hits on Least Active Day	1,836

Most Active Hour of the Day	10:00-10:59
Least Active Hour of the Day	00:00-00:59


Summary of Activity by Time Increment

This section helps you understand the bandwidth requirements of the site by indicating the volume of activity in kilobytes transferred. The table provides various measures of activity by unit of time for the report period (the unit of time depends on the amount of time covered by the report, and will be the day in most cases).



Activity Level by Day of the Week

This section shows the activity for each day of the week for the report period (i.e. if there are two Mondays in the report period, the value presented is the sum of all hits for both Mondays.) Values in the table do not include errored hits.




Activity Level by Day of the Week

	Day	Hits	% of Total Hits	User Sessions
1	Sun	0	0%	0
2	Mon	0	0%	0
3	Tue	0	0%	0
4	Wed	1,836	100%	120
5	Thu	0	0%	0
6	Fri	0	0%	0
7	Sat	0	0%	0
	Total Weekdays	1,836	100%	120
	Total Weekend	0	0	0

Activity Level by Hour of the Day

This section shows the most and the least active hour of the day for the report period. The second table breaks down activity for the given report period to show the average activity for each individual hour of the day (if there are several days in the report period, the value presented is the sum of all hits during that period of time for all days). All times are referenced to the location of the system running the analysis.

Activity Level By Hour of the Day



Activity Level by Hours Details

Hour	# of Hits	% of Total Hits	# of User Sessions
00:00-00:59	0	0%	0
01:00-01:59	0	0%	0
02:00-02:59	0	0%	0

03:00-03:59	0	0%	0
04:00-04:59	1	0.05%	1
05:00-05:59	0	0%	0
06:00-06:59	0	0%	0
07:00-07:59	145	7.89%	10
08:00-08:59	156	8.49%	15
09:00-09:59	50	2.72%	6
10:00-10:59	428	23.31%	8
11:00-11:59	325	17.7%	13
12:00-12:59	52	2.83%	17
13:00-13:59	7	0.38%	2
14:00-14:59	15	0.81%	4
15:00-15:59	118	6.42%	5
16:00-16:59	74	4.03%	2
17:00-17:59	174	9.47%	7
18:00-18:59	115	6.26%	4
19:00-19:59	17	0.92%	4
20:00-20:59	46	2.5%	2
21:00-21:59	70	3.81%	16
22:00-22:59	39	2.12%	0
23:00-23:59	4	0.21%	4
Total Users during Work Hours (8:00am-5:00pm)	1,225	66.72%	72
Total Users during After Hours (5:01pm-7:59am)	611	33.27%	48

Technical Statistics and Analysis

This table shows the total number of hits for the site, how many were successful, how many failed, and calculates the percentage of hits that failed. It may help you in determining the reliability of the site.

Technical Statistics and Analysis	
Total Hits	2,035
Successful Hits	1,836
Failed Hits	199
Failed Hits as Percent	9.77%
Cached Hits	426
Cached Hits as Percent	20.93%


Dynamic Pages & Forms Errors

This section shows the number of successful form submissions compared to the number that failed. WebTrends considers anything with Post command as a dynamic page.

Dynamic Pages & Forms Errors		
Type	Hits	% of Total
Successful Forms Submitted	24	96%
Failed Forms Submitted	1	4%
Total	25	100%

Top Referring Sites

This section identifies the domain names or numeric IP addresses with links to the site. This information will only be displayed if your server is logging this information.




Top Referring Sites		
	Site	User Sessions
1	http://www.genomesecurities.com/	45
2	http://www.emedtrade.com/	25
3	No Referrer	24
4	http://emedtrade.com/	21
5	http://www.genomesecurities.com/	5
	Sub Total for the Referring Sites Above	120
	Total for the Log File	120

Top Referring URLs

This section provides the full URLs of the sites with links to the site. This information will only be displayed if your server is logging the referrer information.

Top Referring URLs



Top Referring URLs

	URL	User Sessions
1	http://www.genomesecurities.com/	38
2	No Referrer	24
3	http://www.emedtrade.com/cistron/idxcontents.htm	13
4	http://emedtrade.com/cistronrequest.htm	8
5	http://emedtrade.com/cistronrequestmain.htm	7
6	http://www.genomesecurities.com/	4
7	http://www.emedtrade.com/cistron/idxmain.htm	4
8	http://emedtrade.com/idxbanner.htm	4
9	http://www.genomesecurities.com/index.html	4
10	http://www.emedtrade.com/cistron/financialcontents.htm	3
11	http://emedtrade.com/cfscript/processform.cfm	2
12	http://www.emedtrade.com/cistron/	2
13	http://www.genomesecurities.com/Principals/principals.html	1
14	http://www.genomesecurities.com/Advisory Board/advisory_board.html	1
15	http://www.emedtrade.com/cistron/science/Science.htm	1
16	http://www.emedtrade.com/cistron/intellectualcontents.htm	1
17	http://www.emedtrade.com/cistron/companycontents.htm	1
18	http://www.genomesecurities.com/Principals/Naismith/naismith.html	1
19	http://www.genomesecurities.com./index.html	1
	Sub Total for the Referrers Above	120
	Total for the Log File	120

Most Used Browsers


This section identifies the most popular WWW Browsers used by visitors to the site. This information will only

http://www.emedtrade.com/_private/stats/yesterday_01_b.html

6/24/99

09667892.05404

be displayed if your server is logging the browser/platform information.



Most Used Browsers				
	Browser	Hits	% of Total Hits	User Sessions
1	Microsoft Internet Explorer	1,246	67.86%	87
2	Netscape	536	29.19%	25
3	Other Netscape Compatible	54	2.94%	8
	Total For Browsers Above	1,836	100%	120

Glossary

Following are definitions for terms used in this report and throughout the World-Wide Web in general. These terms are also common to the WebTrends analysis tool.

Glossary	
Ad	A graphic or a banner on a web page that when clicked on, takes the visitor to another site.
Ad Clicks	A click on an advertisement on a web site which takes a user to another site, it is referred to as an ad click.
Ad Views	A web page that presents an ad. Once the visitor has viewed an ad, he/she can click on it (see Ad Click). There may be more than one ad on an ad view.
Authentication	Technique by which access to internet or Intranet resources requires the user to identify himself or herself by entering a username and password.
Bandwidth	Measure (in kilobytes of data transferred) of the traffic on the site.
Browser	A program used to locate and view HTML documents (Netscape, Mosaic, Microsoft Explorer, for example.)
Click through rate	Percentage of users who click on a viewed advertisement. This is a good indication of the effectiveness of this ad.
Client	The browser (see above) used by a visitor to a Web site.

Client Errors	An error occurring due to an invalid request by the visitor's browser. Client errors are in the 400-range. See "Return Code" definition.
Company Database	The database installed and used by WebTrends to look up the company name, city, state and country corresponding to a specific domain name.
Cookies	Persistent Client-State HTTP Cookies are files containing information about visitors to a web site (e.g., user name and preferences). This information is provided by the user during the first visit to a Web server. The server records this information in a text file and stores this file on the visitor's hard drive. When the visitor accesses the same web site again, the server looks for the cookie and configures itself based on the information provided.
Domain Name	The text name corresponding to the numeric IP address of a computer on the Internet (i.e., www.webtrends.com).
Domain Name Lookup	The process of converting a numeric IP address into a text name (for example, 204.245.240.194 is converted to www.webtrends.com).
Filters	A means of narrowing the scope of a report or view by specifying ranges or types of data to include in or exclude.
Forms	An HTML page which passes variables back to the server. These pages are used to gather information from users. Also referred to as scripts.
FTP	File Transfer Protocol is a standard method of sending files between computers over the Internet.
GIF	Graphics Interchange Format is an image file format commonly used in HTML documents.
Hit	An action on the Web site, such as when a user views a page or downloads a file.
Home Page	The main page of a Web site. The home page provides visitors with an overview and links to the rest of the site. It often contains or links to a Table of contents for the site.
Home Page URL	The local path or Internet URL to the default page of the Web site for which WebTrends reports will be generated.
HTML	Hyper Text Markup Language is used to write documents for the World Wide Web to specify hypertext links between related objects and documents.
HTTP	Hyper Text Transfer Protocol is a standard method of transferring data between a Web server and a Web browser.
IP Address	Internet Protocol address identifying a computer connected to the Internet.
Log File	A file created by a web or proxy server which contains all of the access information regarding the activity on that server.
Page Views	Also called Page Impressions. Hit to HTML pages only (access to non-HTML documents are not counted).
Platform	The operating system (i.e. Windows 95, Windows NT, etc.) used by a visitor to the site.
Protocol	An established method of exchanging data over the Internet.
Referrer	URL of an HTML page that refers to the site.
Return Code	<p>The return status of the request which specifies whether the transfer was successful and why.</p> <p>Possible "Success" codes are:</p> <ul style="list-style-type: none"> 200 = Success: OK 201 = Success: Created 202 = Success: Accepted 203 = Success: Partial Information 204 = Success: No Response 300 = Success: Redirected 301 = Success: Moved 302 = Success: Found

	<p>303 = Success: New Method 304 = Success: Not Modified Possible "Failed" codes are: 400 = Failed: Bad Request 401 = Failed: Unauthorized 402 = Failed: Payment Required 403 = Failed: Forbidden 404 = Failed: Not Found 500 = Failed: Internal Error 501 = Failed: Not Implemented 502 = Failed: Overloaded Temporarily 503 = Failed: Gateway Timeout</p>
Server	A computer that hosts information available to anyone accessing the Internet.
Server Error	An error occurring at the server. Web server errors have codes in the 500 range.
Spiders	An automated program which searches the internet.
Suffix (Domain Name)	<p>The three digit suffix of a domain can be used to identify the type of organization.</p> <p>Possible "Suffixes" are: .com = Commercial .edu = Educational .int = International .gov = Government .mil = Military .net = Network .org = Organization</p>
User Agent	Fields in an extended Web server log file identifying the browser and platform used by a visitor.
URL	Uniform Resource Locator is a means of identifying an exact location on the Internet. For example, http://www.webtrends.com/html/info/default.htm is the URL which defines the use of HTTP to access the Web page Default.htm in the /html/info/ directory on the WebTrends Corporation Web site). As the previous example shows, a URL is comprised of four parts: Protocol Type (HTTP), Machine Name (webtrends.com), Directory Path (/html/info/), and File Name (default.htm).
User Session	A session of activity (all hits) for one user of a web site. A unique user is determined by the IP address or cookie. By default, a user session is terminated when a user is inactive for more than 30 minutes. This duration can be changed from General panel in the Options, Web Log Analysis dialog. Synonym: Visit.
View,Page	Each request for a particular web page which displays an ad. Also referred to as an impression.
Visit	Commonly called User Session. All activity for one user of a web site. By default, a user session is terminated when a user is inactive for more than 30 minutes.



This report was generated by Synapse Imaging.




Yesterday

eMedTrade

General Statistics

The User Profile by Regions graph identifies the general location of the visitors to your Web site. The General Statistics table includes statistics on the total activity for this web site during the designated time frame.




General Statistics	
Date & Time This Report was Generated	Saturday June 26, 1999 - 00:42:11
Timeframe	06/25/99 00:00:00 - 06/25/99 23:59:59
Number of Hits for Home Page	10
Number of Successful Hits for Entire Site	296
Number of Page Views (Impressions)	131
Number of User Sessions	26
User Sessions from United States	53.84%
International User Sessions	23.07%
User Sessions of Unknown Origin	23.07%
Average Number of Hits Per Day	296
Average Number of Page Views Per Day	131
Average Number of User Sessions Per Day	26
Average User Session Length	00:06:13

Number of Unique Users	21
Number of Users Who Visited Once	19
Number of Users Who Visited More Than Once	2

Most Requested Pages

This section identifies the most popular web site pages and how often they were accessed. The average time a user spends viewing a page is also indicated in the table.




Most Requested Pages					
	Pages	Views	% of Total Views	User Sessions	Avg. Time Viewed
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	14	10.68%	11	00:02:46
2	http://emedtrade.com/cistron/	10	7.63%	5	00:00:12
3	EMedTrade.Com - Home Page http://emedtrade.com/	10	7.63%	7	00:03:48
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	9	6.87%	9	00:00:03
5	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	9	6.87%	9	
6	http://emedtrade.com/cistron/idxmain.htm	5	3.81%	4	00:00:02
7	http://emedtrade.com/cistron/idxcontents.htm	5	3.81%	4	00:00:18
8	http://emedtrade.com/cistron/intellectual.htm	4	3.05%	3	
9	http://emedtrade.com/cistron/assessments/other1.htm	3	2.29%	2	00:00:08
10	http://emedtrade.com/cistron/intellectual/Protection.htm	3	2.29%	3	00:00:25
11	http://emedtrade.com/cistron/intellectualcontents.htm	3	2.29%	3	00:00:40
12	http://emedtrade.com/cfscript/processform.cfm	3	2.29%	3	00:04:26

13	http://emedtrade.com/cistron/company/transactionrational.htm	3	2.29%	2	00:00:14
14	http://emedtrade.com/Cistron/revenue/Techne.htm	3	2.29%	2	00:00:50
15	http://emedtrade.com/cistron/intellectual/ForeignPatents.htm	2	1.52%	2	00:00:36
16	http://emedtrade.com/cistron/assessmentscontents.htm	2	1.52%	2	
17	http://emedtrade.com/cistron/assessments.htm	2	1.52%	2	
18	http://emedtrade.com/cistron/assessments/DrDinarello.htm	2	1.52%	1	00:00:07
19	http://emedtrade.com/cistron/company.htm	2	1.52%	2	00:00:01
20	http://emedtrade.com/cistron/intellectual/Licenses.htm	2	1.52%	2	00:00:23
21	http://emedtrade.com/cistron/companycontents.htm	2	1.52%	2	00:00:25
22	http://emedtrade.com/cistron/company/management.htm	2	1.52%	2	00:01:24
23	http://emedtrade.com/cistron/intellectual/USPatents.htm	2	1.52%	2	00:00:19
24	http://emedtrade.com/cistron/sciencecontents.htm	2	1.52%	2	00:00:13
25	http://emedtrade.com/cistron/science.htm	2	1.52%	2	00:00:01
26	http://emedtrade.com/cistron/science/Science.htm	2	1.52%	2	00:00:10
27	http://emedtrade.com/cistron/revenue.htm	2	1.52%	2	
28	http://emedtrade.com/cistron/revenuecontents.htm	2	1.52%	2	
29	http://emedtrade.com/cistron/assessments/ProAssessments.htm	2	1.52%	2	00:00:37
30	http://emedtrade.com/cistron/financialcontents.htm	1	0.76%	1	00:00:03
31	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	1	0.76%	1	00:02:05
32	http://emedtrade.com/cistron/company/employees.htm	1	0.76%	1	00:00:22
33	http://emedtrade.com/cistron/company/busoverview.htm	1	0.76%	1	00:02:19
34	http://emedtrade.com/cistron/financial.htm	1	0.76%	1	00:00:01
35	http://emedtrade.com/Cistron/research/Pasteur.htm	1	0.76%	1	
36	http://emedtrade.com/Cistron/research.htm	1	0.76%	1	
37	http://emedtrade.com/Cistron/researchcontents.htm	1	0.76%	1	00:00:26
38	http://emedtrade.com/Cistron/science/Research/rheumatoid.htm	1	0.76%	1	00:00:42
39	http://emedtrade.com/Cistron/science/Research/biologicalproperties.htm	1	0.76%	1	00:00:12
40	http://emedtrade.com/Cistron/assessments/other.htm	1	0.76%	1	00:01:04
	Sub Total For the Page Views Above	125	95.41%	N/A	N/A
	Total For the Log File	131	100%	N/A	N/A

Least Requested Pages

This section identifies the least popular pages on your Web site, and how often they were accessed.

Least Requested Pages




Least Requested Pages

	Pages	Views	% of Total Views	User Sessions
1	http://emedtrade.com/Cistron/corporatecontents.htm	1	0.76%	1
2	http://emedtrade.com/Cistron/corporate/Corporate.htm	1	0.76%	1
3	http://emedtrade.com/Cistron/corporate.htm	1	0.76%	1
4	http://emedtrade.com/Cistron/secfilings/cistronfilings.htm	1	0.76%	1
5	http://emedtrade.com/Cistron/filingscontents.htm	1	0.76%	1
6	http://emedtrade.com/Cistron/filings.htm	1	0.76%	1
7	http://emedtrade.com/Cistron/assessments/other.htm	1	0.76%	1
8	http://emedtrade.com/Cistron/science/Research/biologicalproperties.htm	1	0.76%	1
9	http://emedtrade.com/Cistron/science/Research/rheumatoid.htm	1	0.76%	1
10	http://emedtrade.com/Cistron/researchcontents.htm	1	0.76%	1
11	http://emedtrade.com/Cistron/research.htm	1	0.76%	1
12	http://emedtrade.com/Cistron/research/Pasteur.htm	1	0.76%	1
13	http://emedtrade.com/cistron/financial.htm	1	0.76%	1
14	http://emedtrade.com/cistron/company/busoverview.htm	1	0.76%	1
15	http://emedtrade.com/cistron/company/employees.htm	1	0.76%	1
16	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	1	0.76%	1
17	http://emedtrade.com/cistron/financialcontents.htm	1	0.76%	1
18	http://emedtrade.com/cistron/assessments/ProAssessments.htm	2	1.52%	2
19	http://emedtrade.com/cistron/revenuecontents.htm	2	1.52%	2
20	http://emedtrade.com/cistron/revenue.htm	2	1.52%	2
21	http://emedtrade.com/cistron/science/Science.htm	2	1.52%	2
22	http://emedtrade.com/cistron/science.htm	2	1.52%	2
23	http://emedtrade.com/cistron/sciencecontents.htm	2	1.52%	2
24	http://emedtrade.com/cistron/intellectual/USPatents.htm	2	1.52%	2

25	http://emedtrade.com/cistron/company/management.htm	2	1.52%	2
26	http://emedtrade.com/cistron/companycontents.htm	2	1.52%	2
27	http://emedtrade.com/cistron/intellectual/Licenses.htm	2	1.52%	2
28	http://emedtrade.com/cistron/company.htm	2	1.52%	2
29	http://emedtrade.com/cistron/assessments/DrDinareello.htm	2	1.52%	1
30	http://emedtrade.com/cistron/assessments.htm	2	1.52%	2

Top Entry Pages


This section identifies the first page viewed when a user visits this site. This is most likely your home page but, in some cases, it may also be specific URLs that users enter to access a particular page directly. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not be counted as an Entry Page, and the session is not counted in the total.



Top Entry Pages			
	File	% of Total	User Sessions
1	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	36.84%	7
2	EMedTrade.Com - Home Page http://emedtrade.com/	36.84%	7
3	http://emedtrade.com/cistron/	10.52%	2
4	http://emedtrade.com/cistron/assessments/other1.htm	5.26%	1
5	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	5.26%	1
6	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	5.26%	1
	Total For the Pages Above	100%	19

Top Exit Pages

This section identifies the pages users were on when they left the site. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as an Exit Page, and the session is not counted in the total.




Top Exit Pages			
	Pages	% of Total	User Sessions
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	31.57%	6
2	EMedTrade.Com - Home Page http://emedtrade.com/	26.31%	5
3	http://emedtrade.com/cistron/assessments/other1.htm	5.26%	1
4	http://emedtrade.com/cistron/company/management.htm	5.26%	1
5	http://emedtrade.com/cistron/intellectualcontents.htm	5.26%	1
6	http://emedtrade.com/Cistron/corporatecontents.htm	5.26%	1
7	http://emedtrade.com/cistron/intellectual/ForeignPatents.htm	5.26%	1
8	http://emedtrade.com/cfscript/processform.cfm	5.26%	1
9	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	5.26%	1
10	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	5.26%	1
Total For the Pages Above (only sessions starting on a valid document type are included)		100%	19

Single Access Pages

This section identifies the pages on the site that visitors access and exit without viewing any other page. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session


started on a document with a different type (such as a graphic or sound file), the file is not counted as a Single Access Page, and the session is not counted in the total




Single Access Pages			
	Pages	% of Total	User Sessions
1	EMedTrade.Com - Home Page http://emedtrade.com/	55.55%	5
2	http://emedtrade.com/cistron/assessments/other1.htm	11.11%	1
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	11.11%	1
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	11.11%	1
5	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	11.11%	1
Total For the Pages Above		100%	9

Most Downloaded File Types

This section identifies the accessed file types and the total kilobytes downloaded for each file type. Cached requests and erred hits are excluded from the totals.






Most Downloaded File Types			
	File type	Files	K Bytes Transferred
1	htm	128	391
2	GIF	127	457
3	jpg	19	216
4	cfm	3	5
Total Files & K Bytes Transferred		277	1,068

Most Active Countries

This section identifies the top locations of the visitors to the site by country. The country of the user is determined by the suffix of their domain name. Use this information carefully because this information is based on where the domain name of the visitor is registered, and may not always be an accurate identifier of the actual geographic location of this visitor. For example, while a vast majority of .com domain names are from the United States, there is a small minority of domain names that exist outside of the United States.




Most Active Countries		
	Countries	User Sessions
1	United States	14
2	UK	3

3	Germany	2
4	Switzerland	1
	Total	20

North American States and Provinces

This section breaks down web site activity to show which of the North American States and Provinces were the most active on the site. This information is based on where the domain name of the visitor is registered, and may not always be an accurate representation of the actual geographic location of this visitor. This information can only be displayed if reverse DNS lookups have been performed.




North American States & Provinces		
	State	User Sessions
1	Virginia	7
2	New Jersey	1
3	Washington	1
4	California	1
	Total For the States Above	10

Most Active Organizations

This section identifies the companies or organizations that accessed the site the most often.

Most Active Organizations




Most Active Organizations

	Organizations	Hits	% of Total Hits	User Sessions
1	parkedale.com	87	29.39%	1
2	Uunet Technologies Inc. uu.net	51	17.22%	1
3	ns.ibo.ch	47	15.87%	1
4	Spacenet GmbH Space.Net	39	13.17%	1
5	208.169.102.230	14	4.72%	6
6	xpc-mii.net	11	3.71%	1
7	Berlex Laboratories berlex.com	8	2.7%	1
8	gw.byk.de	6	2.02%	1
9	At&T Easylink Services att.net	6	2.02%	1
10	Demon Internet demon.co.uk	6	2.02%	1
11	America Online aol.com	6	2.02%	6
12	netcraft.co.uk	5	1.68%	2
13	The Boeing Company boeing.com	4	1.35%	1
14	intiques.net	3	1.01%	1
15	chiron.com	3	1.01%	1
	Sub Total For Companies Above	296	100%	26
	Total For the Log File	296	100%	26

Organization Breakdown


This section provides a breakdown by types of organizations (.com, .net, .edu, .org, .mil, and .gov.) This information can only be displayed if reverse DNS lookups have been performed, and the percentages refer to the total of hits for which the organization type can be determined (some IPs cannot be resolved to a domain, and therefore an organization type cannot be determined).




Organization Breakdown				
	Organization Type	Hits	% of Total Hits	User Sessions
1	Company	119	51.96%	13
2	Network	110	48.03%	5
	Total for Known Organization Types	229	100%	18

Summary of Activity by Time Increment

This section helps you understand the bandwidth requirements of the site by indicating the volume of activity in kilobytes transferred. The table provides various measures of activity by unit of time for the report period (the unit of time depends on the amount of time covered by the report, and will be the day in most cases).






Activity Level by Day of the Week

This section shows the activity for each day of the week for the report period (i.e. if there are two Mondays in the report period, the value presented is the sum of all hits for both Mondays.) Values in the table do not include erred hits.

Activity Level By Day of the Week



Activity Level by Day of the Week


	Day	Hits	% of Total Hits	User Sessions
1	Sun	0	0%	0
2	Mon	0	0%	0
3	Tue	0	0%	0
4	Wed	0	0%	0
5	Thu	0	0%	0
6	Fri	296	100%	26
7	Sat	0	0%	0
	Total Weekdays	296	100%	26
	Total Weekend	0	0	0

Activity Level by Hour of the Day

This section shows the most and the least active hour of the day for the report period. The second table

breaks down activity for the given report period to show the average activity for each individual hour of the day (if there are several days in the report period, the value presented is the sum of all hits during that period of time for all days). All times are referenced to the location of the system running the analysis.

Activity Level By Hour of the Day




Activity Level by Hours Details

Hour	# of Hits	% of Total Hits	# of User Sessions
00:00-00:59	3	1.01%	1
01:00-01:59	0	0%	0
02:00-02:59	0	0%	0
03:00-03:59	1	0.33%	1
04:00-04:59	0	0%	0
05:00-05:59	53	17.9%	2
06:00-06:59	3	1.01%	1
07:00-07:59	6	2.02%	1
08:00-08:59	101	34.12%	3
09:00-09:59	0	0%	0
10:00-10:59	6	2.02%	1
11:00-11:59	2	0.67%	1
12:00-12:59	87	29.39%	1
13:00-13:59	11	3.71%	3
14:00-14:59	0	0%	0
15:00-15:59	16	5.4%	8
16:00-16:59	2	0.67%	1
17:00-17:59	0	0%	0
18:00-18:59	2	0.67%	1
19:00-19:59	3	1.01%	1
20:00-20:59	0	0%	0
21:00-21:59	0	0%	0
22:00-22:59	0	0%	0

23:00-23:59	0	0%	0
Total Users during Work Hours (8:00am-5:00pm)	225	76.01%	18
Total Users during After Hours (5:01pm-7:59am)	71	23.98%	8

Top Referring Sites

This section identifies the domain names or numeric IP addresses with links to the site. This information will only be displayed if your server is logging this information.




Top Referring Sites		
	Site	User Sessions
1	http://www.genomesecurities.com/	7
2	No Referrer	6
3	http://emedtrade.com/	5
4	http://www.genomesecurities.com/	4
5	http://www.emedtrade.com/	2
6	http://www.netcraft.com/	2
Sub Total for the Referring Sites Above		26
Total for the Log File		26

Top Referring URLs

This section provides the full URLs of the sites with links to the site. This information will only be displayed if your server is logging the referrer information.

Top Referring URLs




Top Referring URLs

	URL	User Sessions
1	No Referrer	6
2	http://www.genomesecurities.com/	5
3	http://www.genomesecurities.com/	2
4	http://www.genomesecurities.com/index.html	2
5	http://emedtrade.com/cistronrequest.htm	2
6	http://emedtrade.com/cistronrequestmain.htm	2
7	http://www.netcraft.com/	2
8	http://www.emedtrade.com/cistron	1
9	http://www.emedtrade.com/_private/stats/yesterday_01_b.html	1
10	http://emedtrade.com/idxbanner.htm	1
11	http://www.genomesecurities.com./Principals/DeNucci/Denucci.html	1
12	http://www.genomesecurities.com./Contact_Us/contact_us.html	1
Sub Total for the Referrers Above		26
Total for the Log File		26

Most Used Browsers

This section identifies the most popular WWW Browsers used by visitors to the site. This information will only be displayed if your server is logging the browser/platform information.

Most Used Browsers



Most Used Browsers

	Browser	Hits	% of Total Hits	User Sessions
1	Microsoft Internet Explorer	173	58.44%	14
2	Netscape	99	33.44%	5
3	minixpc/0.9	11	3.71%	1
4	MSPProxy/2.0	8	2.7%	4
5	Others	5	1.68%	2
	Total For Browsers Above	296	100%	26

Glossary

Glossary	
Ad Clicks	A click on an advertisement on a web site which takes a user to another site, it is referred to as an ad click.
Ad Views	A web page that presents an ad. Once the visitor has viewed an ad, he/she can click on it (see Ad Click). There may be more than one ad on an ad view.
Authentication	Technique by which access to Internet or Intranet resources requires the user to identify himself or herself by entering a username and password.
Bandwidth	Measure (in kilobytes of data transferred) of the traffic on the site.
Browser	A program used to locate and view HTML documents (Netscape, Mosaic, Microsoft Explorer, for example.)
Click through rate	Percentage of users who click on a viewed advertisement. This is a good indication of the effectiveness of this ad.
Client	The browser (see above) used by a visitor to a Web site.
Client Errors	An error occurring due to an invalid request by the visitor's browser. Client errors are in the 400-range. See "Return Code" definition.

Company Database	The database installed and used by WebTrends to look up the company name, city, state and country corresponding to a specific domain name.
Cookies	Persistent Client-State HTTP Cookies are files containing information about visitors to a web site (e.g., user name and preferences). This information is provided by the user during the first visit to a Web server. The server records this information in a text file and stores this file on the visitor's hard drive. When the visitor accesses the same web site again, the server looks for the cookie and configures itself based on the information provided.
Domain Name	The text name corresponding to the numeric IP address of a computer on the Internet (i.e., www.webtrends.com).
Domain Name Lookup	The process of converting a numeric IP address into a text name (for example, 204.245.240.194 is converted to www.webtrends.com).
FTP	File Transfer Protocol is a standard method of sending files between computers over the Internet.
Filters	A means of narrowing the scope of a report or view by specifying ranges or types of data to include in or exclude.
Forms	An HTML page which passes variables back to the server. These pages are used to gather information from users. Also referred to as scripts.
GIF	Graphics Interchange Format is an image file format commonly used in HTML documents.
HTML	Hyper Text Markup Language is used to write documents for the World Wide Web to specify hypertext links between related objects and documents.
HTTP	Hyper Text Transfer Protocol is a standard method of transferring data between a Web server and a Web browser.
Hit	An action on the Web site, such as when a user views a page or downloads a file.
Home Page	The main page of a Web site. The home page provides visitors with an overview and links to the rest of the site. It often contains or links to a Table of contents for the site.
Home Page URL	The local path or Internet URL to the default page of the Web site for which WebTrends reports will be generated.
IP Address	Internet Protocol address identifying a computer connected to the Internet.
Log File	A file created by a web or proxy server which contains all of the access information regarding the activity on that server.
Page Views	Also called Page Impressions. Hit to HTML pages only (access to non-HTML documents are not counted).
Platform	The operating system (i.e. Windows 95, Windows NT, etc.) used by a visitor to the site.
Protocol	An established method of exchanging data over the Internet.
Referrer	URL of an HTML page that refers to the site.
Return Code	<p>The return status of the request which specifies whether the transfer was successful and why.</p> <p>Possible "Success" codes are:</p> <ul style="list-style-type: none"> 200 = Success: OK 201 = Success: Created 202 = Success: Accepted 203 = Success: Partial Information 204 = Success: No Response 300 = Success: Redirected 301 = Success: Moved 302 = Success: Found 303 = Success: New Method 304 = Success: Not Modified

	<p>Possible "Failed" codes are:</p> <p>400 = Failed: Bad Request 401 = Failed: Unauthorized 402 = Failed: Payment Required 403 = Failed: Forbidden 404 = Failed: Not Found 500 = Failed: Internal Error 501 = Failed: Not Implemented 502 = Failed: Overloaded Temporarily 503 = Failed: Gateway Timeout</p>
Server	A computer that hosts information available to anyone accessing the Internet.
Server Error	An error occurring at the server. Web server errors have codes in the 500 range.
Spiders	An automated program which searches the internet.
Suffix (Domain Name)	<p>The three digit suffix of a domain can be used to identify the type of organization.</p> <p>Possible "Suffixes" are:</p> <p>.com = Commercial .edu = Educational .int = International .gov = Government .mil = Military .net = Network .org = Organization</p>
URL	Uniform Resource Locator is a means of identifying an exact location on the Internet. For example, http://www.webtrends.com/html/info/default.htm is the URL which defines the use of HTTP to access the Web page Default.htm in the /html/info/ directory on the WebTrends Corporation Web site). As the previous example shows, a URL is comprised of four parts: Protocol Type (HTTP), Machine Name (webtrends.com), Directory Path (/html/info/), and File Name (default.htm).
User Agent	Fields in an extended Web server log file identifying the browser and platform used by a visitor.
User Session	A session of activity (all hits) for one user of a web site. A unique user is determined by the IP address or cookie. By default, a user session is terminated when a user is inactive for more than 30 minutes. This duration can be changed from General panel in the Options, Web Log Analysis dialog. Synonym: Visit.
View,Page	Each request for a particular web page which displays an ad. Also referred to as an impression.
Visit	Commonly called User Session. All activity for one user of a web site. By default, a user session is terminated when a user is inactive for more than 30 minutes.



This report was generated by WebTrends.

WebTrends is a registered trademark and CommerceTrends is a trademark of WebTrends Corporation. Other trademarks are the property of their respective owners.

09867832_053001




Last Week

eMedTrade

General Statistics

The User Profile by Regions graph identifies the general location of the visitors to your Web site. The General Statistics table includes statistics on the total activity for this web site during the designated time frame.




General Statistics	
Date & Time This Report was Generated	Sunday June 27, 1999 - 02:08:10
Timeframe	06/20/99 00:00:00 - 06/26/99 23:59:59
Number of Hits for Home Page	73
Number of Successful Hits for Entire Site	4,417
Number of Page Views (Impressions)	1,667
Number of User Sessions	286
User Sessions from United States	64.33%
International User Sessions	7.34%
User Sessions of Unknown Origin	28.32%
Average Number of Hits Per Day	631
Average Number of Page Views Per Day	238
Average Number of User Sessions Per Day	40
Average User Session Length	00:05:30

Number of Unique Users	169
Number of Users Who Visited Once	139
Number of Users Who Visited More Than Once	30

Most Requested Pages

This section identifies the most popular web site pages and how often they were accessed. The average time a user spends viewing a page is also indicated in the table.





Most Requested Pages					
	Pages	Views	% of Total Views	User Sessions	Avg. Time Viewed
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	231	13.85%	146	00:00:55
2	http://emedtrade.com/cistron/	138	8.27%	61	00:00:17
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	125	7.49%	117	00:01:02
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	120	7.19%	115	00:00:12
5	http://emedtrade.com/cistron/idxcontents.htm	77	4.61%	52	00:00:22
6	http://emedtrade.com/cistron/idxmain.htm	76	4.55%	52	00:00:29
7	EMedTrade.Com - Home Page http://emedtrade.com/	73	4.37%	63	00:03:53
8	http://emedtrade.com/cfscript/processform.cfm	43	2.57%	33	00:02:49
9	http://emedtrade.com/cistron/assessmentcontents.htm	38	2.23%	28	00:00:12
10	http://emedtrade.com/cistron/assessments/ProAssessments.htm	38	2.15%	24	00:00:38
11	http://emedtrade.com/cistron/assessments.htm	38	2.09%	20	00:00:02
12	http://emedtrade.com/Cistron/company/transactionnational.htm	35	2.00%	28	00:00:20

13	http://emedtrade.com/Cistron/companycontents.htm	34	2.03%	28	00:00:12
14	http://emedtrade.com/Cistron/company.htm	33	1.97%	28	00:00:14
15	http://emedtrade.com/cistron/revenue/Techno.htm	25	1.49%	22	00:00:38
16	http://emedtrade.com/cistron/Intellectual.htm	24	1.43%	23	00:00:05
17	http://emedtrade.com/cistron/intellectual/Protection.htm	24	1.43%	23	00:00:18
18	http://emedtrade.com/cistron/intellectualcontents.htm	23	1.37%	23	00:00:23
19	http://emedtrade.com/cistron/revenue.htm	21	1.25%	21	00:00:02
20	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	21	1.25%	19	00:00:44
21	http://emedtrade.com/cistron/revenuecontents.htm	21	1.25%	21	00:00:05
22	http://emedtrade.com/cistron/financialcontents.htm	20	1.19%	19	00:00:04
23	http://emedtrade.com/cistron/financial.htm	20	1.19%	19	00:00:01
24	http://emedtrade.com/cistron/company/management.htm	20	1.19%	18	00:00:33
25	http://emedtrade.com/cistron/science.htm	18	1.07%	16	00:00:05
26	http://emedtrade.com/cistron/science/Science.htm	17	1.01%	16	00:00:32
27	http://emedtrade.com/cistron/sciencecontents.htm	16	0.95%	16	00:00:08
28	http://emedtrade.com/cistron/research/Pasteur.htm	16	0.95%	14	00:00:14
29	http://emedtrade.com/cistron/assessments/other1.htm	15	0.89%	6	00:03:11
30	http://emedtrade.com/cistron/research.htm	15	0.89%	14	00:00:01
31	http://emedtrade.com/cistron/researchcontents.htm	15	0.89%	14	00:00:14
32	http://emedtrade.com/cistron/corporate.htm	15	0.89%	15	00:00:02
33	http://emedtrade.com/cistron/corporate/Corporate.htm	15	0.89%	14	00:00:01
34	http://emedtrade.com/cistron/corporatecontents.htm	14	0.83%	14	00:00:08
35	http://emedtrade.com/cistron/secfilings/cistronfilings.htm	14	0.83%	13	00:00:18
36	http://emedtrade.com/Cistron/company/busoverview.htm	14	0.83%	14	00:01:07
37	http://emedtrade.com/cistron/filings.htm	13	0.77%	13	00:00:01
38	http://emedtrade.com/cistron/filingscontents.htm	13	0.77%	13	00:00:02
39	http://emedtrade.com/cistron/company/employees.htm	13	0.77%	13	00:00:14
40	http://emedtrade.com/cistron/intellectual/USPatents.htm	11	0.65%	10	00:00:57
Sub Total For the Page Views Above		1,547	92.8%	N/A	N/A
Total For the Log File		1,667	100%	N/A	N/A

Least Requested Pages

This section identifies the least popular pages on your Web site, and how often they were accessed.






Least Requested Pages

	Pages	Views	% of Total Views	User Sessions
1	http://emedtrade.com/cistron/secfilings/recent2.htm	1	0.05%	1
2	http://emedtrade.com/cistron/secfilings/recent1.htm	1	0.05%	1
3	http://emedtrade.com/cistron/science/IC8-bioassay.htm	1	0.05%	1
4	http://emedtrade.com/cistron/secfilings/exhibits.htm	2	0.11%	2
5	http://emedtrade.com/cistron/science/NeutralizationStudy1.htm	2	0.11%	2
6	http://emedtrade.com/cistron/assessments/DrRosenwasser.htm	2	0.11%	2
7	http://emedtrade.com/cistron/assessments/GVHD.htm	2	0.11%	2
8	http://emedtrade.com/cistron/science/IC8-bioassay1.htm	3	0.17%	3
9	http://emedtrade.com/cistron/science/Regulation-of-Nitric-Oxide.htm	3	0.17%	3
10	http://emedtrade.com/cistron/secfilings/recent.htm	3	0.17%	3
11	http://emedtrade.com/cistron/science/IL-1B-mab1.htm	3	0.17%	3
12	http://emedtrade.com/cistron/assessments/DrLust.htm	4	0.23%	4
13	http://emedtrade.com/cistron/science/Research/effectsoftreatment.htm	4	0.23%	4
14	http://emedtrade.com/cistron/science/Research/Antitumoureffects.htm	4	0.23%	4
15	http://emedtrade.com/cistron/financials/Sumofops.htm	4	0.23%	4
16	http://emedtrade.com/cistron/financials/historical.htm	5	0.29%	5
17	http://emedtrade.com/cistron/science/Research/rheumatoid.htm	5	0.29%	5
18	http://emedtrade.com/cistron/science/Research/biologicalproperties.htm	5	0.29%	5
19	http://emedtrade.com/cistron/assessments/Arthritis.htm	7	0.41%	5
20	http://emedtrade.com/cistron/assessments/other.htm	7	0.41%	7
21	http://emedtrade.com/cistron/assessments/versus.htm	7	0.41%	6
22	http://emedtrade.com/cistron/assessments/DrAmin.htm	8	0.47%	7
23	http://emedtrade.com/cistron/intellectual/ForeignPatents.htm	8	0.47%	8
24	http://emedtrade.com/cistron/financials/ratio.htm	9	0.53%	8
25	http://emedtrade.com/cistron/assessments/DrDinareello.htm	9	0.53%	8
26	http://emedtrade.com/cistron/intellectual/Licenses.htm	11	0.65%	11
27	http://emedtrade.com/cistron/intellectual/USPatents.htm	11	0.65%	10
28	http://emedtrade.com/cistron/company/employees.htm	13	0.77%	13
29	http://emedtrade.com/cistron/filingscontents.htm	13	0.77%	13
30	http://emedtrade.com/cistron/filings.htm	13	0.77%	13

Top Entry Pages

This section identifies the first page viewed when a user visits this site. This is most likely your home page but, in some cases, it may also be specific URLs that users enter to access a particular page directly. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not be counted as an Entry Page, and the session is not counted in the total.




Top Entry Pages			
	File	% of Total	User Sessions
1	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	40.92%	97
2	EMedTrade.Com - Home Page http://emedtrade.com/	20.25%	48
3	http://emedtrade.com/cistron/	14.76%	35
4	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	9.7%	23
5	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	4.21%	10
6	http://emedtrade.com/cistron/idxcontents.htm	1.26%	3
7	http://emedtrade.com/cistron/company.htm	1.26%	3
8	http://emedtrade.com/cfscript/processform.cfm	0.84%	2
9	http://emedtrade.com/cistron/company/transactionrational.htm	0.84%	2
10	http://emedtrade.com/cistron/financialcontents.htm	0.84%	2
11	http://emedtrade.com/cistron/financials/ratio.htm	0.84%	2
12	http://emedtrade.com/cistron/intellectual/Protection.htm	0.42%	1
13	http://emedtrade.com/cistron/sciencecontents.htm	0.42%	1
14	http://emedtrade.com/cistron/company/employees.htm	0.42%	1
15	http://emedtrade.com/cistron/corporate.htm	0.42%	1
16	http://emedtrade.com/cistron/corporatecontents.htm	0.42%	1

17	http://emedtrade.com/cistron/assessments/DrDinareello.htm	0.42%	1
18	http://emedtrade.com/cistron/financial.htm	0.42%	1
19	http://emedtrade.com/cistron/assessments.htm	0.42%	1
20	http://emedtrade.com/cistron/assessments/ProAssessments.htm	0.42%	1
Total For the Pages Above		99.57%	236

Top Exit Pages

This section identifies the pages users were on when they left the site. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as an Exit Page, and the session is not counted in the total.




Top Exit Pages			
	Pages	% of Total	User Sessions
1	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	28.69%	68
2	EMedTrade.Com - Home Page http://emedtrade.com/	17.29%	41
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	10.97%	26
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	5.48%	13
5	http://emedtrade.com/cfscrip/processform.cfm	5.06%	12
6	http://emedtrade.com/cistron/idxcontents.htm	3.37%	8
7	http://emedtrade.com/cistron/	2.95%	7
8	http://emedtrade.com/cistron/idxmain.htm	2.53%	6
9	http://emedtrade.com/cistron/intellectualcontents.htm	2.1%	5
10	http://emedtrade.com/cistron/financials/3rdquarter10q.htm	1.68%	4
11	http://emedtrade.com/cistron/company/management.htm	1.68%	4

12	http://emedtrade.com/cistron/financialcontents.htm	1.26%	3
13	http://emedtrade.com/cistron/corporate/Corporate.htm	1.26%	3
14	http://emedtrade.com/cistron/assessments/other1.htm	1.26%	3
15	http://emedtrade.com/cistron/companycontents.htm	1.26%	3
Total For the Pages Above (only sessions starting on a valid document type are included)		86.91%	206

Single Access Pages

This section identifies the pages on the site that visitors access and exit without viewing any other page. The percentages refer to the total number of user sessions that started with a valid Document Type. If the session started on a document with a different type (such as a graphic or sound file), the file is not counted as a Single Access Page, and the session is not counted in the total




Single Access Pages			
	Pages	% of Total	User Sessions
1	EMedTrade.Com - Home Page http://emedtrade.com/	43.58%	34
2	Cistron - Index Page Banner http://emedtrade.com/idxbanner.htm	15.38%	12
3	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequest.htm	12.82%	10
4	eMedtrade - Cistron Biotechnology http://emedtrade.com/cistronrequestmain.htm	6.41%	5
5	http://emedtrade.com/cistron/	5.12%	4
6	http://emedtrade.com/cistron/company.htm	2.56%	2
7	http://emedtrade.com/cistron/financialcontents.htm	2.56%	2
8	http://emedtrade.com/cistron/idxcontents.htm	2.56%	2
9	http://emedtrade.com/cistron/intellectual/Protection.htm	1.28%	1
10	http://emedtrade.com/cistron/sciencecontents.htm	1.28%	1

Total For the Pages Above	93.58%	73
---------------------------	--------	----

Most Downloaded File Types


This section identifies the accessed file types and the total kilobytes downloaded for each file type. Cached requests and erred hits are excluded from the totals.




Most Downloaded File Types			
	File type	Files	K Bytes Transferred
1	htm	1,624	5,075
2	GIF	1,555	5,724
3	jpg	204	2,365
4	cfm	43	61
Total Files & K Bytes Transferred		3,426	13,222

Dynamic Pages & Forms

This section identifies the most popular dynamic pages and forms executed by the server. WebTrends counts any line with a Post command or a Get command with a "?" as a dynamic page, and shows only successful hits.






Dynamic Pages & Forms				
	Dynamic Pages	No. of Pages	% of Total	User Sessions
1	http://emedtrade.com/cfscript/processform.cfm	24	100%	17

Most Active Countries

This section identifies the top locations of the visitors to the site by country. The country of the user is determined by the suffix of their domain name. Use this information carefully because this information is based on where the domain name of the visitor is registered, and may not always be an accurate identifier of the actual geographic location of this visitor. For example, while a vast majority of .com domain names are from the United States, there is a small minority of domain names that exist outside of the United States.




Most Active Countries		
	Countries	User Sessions
1	United States	184
2	UK	11
3	Switzerland	4
4	Germany	2
5	Italy	1

6	Australia	1
7	Czech Republic	1
8	Canada	1
	Total	205

North American States and Provinces


This section breaks down web site activity to show which of the North American States and Provinces were the most active on the site. This information is based on where the domain name of the visitor is registered, and may not always be an accurate representation of the actual geographic location of this visitor. This information can only be displayed if reverse DNS lookups have been performed.



North American States & Provinces		
	State	User Sessions
1	Virginia	76
2	California	11
3	Washington	4
4	Utah	4
5	Massachusetts	3
6	Georgia	2
7	New Jersey	2
8	Illinois	2
9	Pennsylvania	2
10	Arizona	1
	Total For the States Above	107

Most Active Organizations

This section identifies the companies or organizations that accessed the site the most often.




Most Active Organizations				
	Organizations	Hits	% of Total Hits	User Sessions
1	intiques.net	512	11.59%	10
2	208.169.102.230	464	10.5%	48
3	209.146.61.155	343	7.76%	7
4	Corixa Corp. corixa.com	303	6.85%	1
5	209.227.18.200	192	4.34%	2
6	America Online aol.com	188	4.25%	68
7	mrc.ac.uk	176	3.98%	3
8	antexbio.com	167	3.78%	1
9	Myriad Genetics myriad.com	141	3.19%	4
10	Unet Technologies Inc. uu.net	135	3.05%	8
11	ns.ibo.ch	125	2.82%	3
12	204.57.233.144	120	2.71%	2
13	mobilenetics.com	110	2.49%	4
14	voicenet.com	106	2.39%	2
15	208.246.201.71	87	1.96%	1
16	parkedale.com	87	1.96%	1
17	superlink.net	85	1.92%	5
18	vertonet.com	84	1.9%	19
19	At&T Easylink Services att.net	73	1.65%	2
20	flashcom.net	70	1.58%	1

Sub Total For Companies Above	3,568	80.77%	192
Total For the Log File	4,417	100%	286

Organization Breakdown


This section provides a breakdown by types of organizations (.com, .net, .edu, .org, .mil, and .gov.) This information can only be displayed if reverse DNS lookups have been performed, and the percentages refer to the total of hits for which the organization type can be determined (some IPs cannot be resolved to a domain, and therefore an organization type cannot be determined).



Organization Breakdown				
	Organization Type	Hits	% of Total Hits	User Sessions
1	Company	1,543	54.73%	154
2	Network	1,078	38.24%	38
3	Education	198	7.02%	5
	Total for Known Organization Types	2,819	100%	197


Summary of Activity by Time Increment

This section helps you understand the bandwidth requirements of the site by indicating the volume of activity in kilobytes transferred. The table provides various measures of activity by unit of time for the report period (the unit of time depends on the amount of time covered by the report, and will be the day in most cases).



Activity Level by Day of the Week

This section shows the activity for each day of the week for the report period (i.e. if there are two Mondays in the report period, the value presented is the sum of all hits for both Mondays.) Values in the table do not include erred hits.




Activity Level by Day of the Week				
	Day	Hits	% of Total Hits	User Sessions
1	Sun	27	0.61%	10
2	Mon	97	2.19%	18
3	Tue	201	4.55%	21
4	Wed	1,836	41.56%	120

5	Thu	1,935	43.8%	81
6	Fri	297	6.72%	27
7	Sat	24	0.54%	9
Total Weekdays		4,366	98.84%	267
Total Weekend		51	1.15%	19

Activity Level by Hour of the Day

This section shows the most and the least active hour of the day for the report period. The second table breaks down activity for the given report period to show the average activity for each individual hour of the day (if there are several days in the report period, the value presented is the sum of all hits during that period of time for all days). All times are referenced to the location of the system running the analysis.



Activity Level by Hours Details

Hour	# of Hits	% of Total Hits	# of User Sessions
00:00-00:59	13	0.29%	4
01:00-01:59	15	0.33%	5
02:00-02:59	7	0.15%	2
03:00-03:59	28	0.63%	5
04:00-04:59	2	0.04%	2
05:00-05:59	65	1.47%	4
06:00-06:59	99	2.24%	4
07:00-07:59	274	6.2%	22
08:00-08:59	262	5.93%	22
09:00-09:59	94	2.12%	13
10:00-10:59	574	12.99%	18
11:00-11:59	643	14.55%	26
12:00-12:59	732	16.57%	28

13:00-13:59	267	6.04%	13
14:00-14:59	199	4.5%	15
15:00-15:59	350	7.92%	22
16:00-16:59	96	2.17%	8
17:00-17:59	278	6.29%	15
18:00-18:59	148	3.35%	10
19:00-19:59	46	1.04%	15
20:00-20:59	56	1.26%	5
21:00-21:59	72	1.63%	18
22:00-22:59	49	1.1%	5
23:00-23:59	48	1.08%	5
Total Users during Work Hours (8:00am-5:00pm)	3,217	72.83%	165
Total Users during After Hours (5:01pm-7:59am)	1,200	27.16%	121


Dynamic Pages & Forms Errors

This section shows the number of successful form submissions compared to the number that failed. WebTrends considers anything with Post command as a dynamic page.

Dynamic Pages & Forms Errors		
Type	Hits	% of Total
Successful Forms Submitted	24	96%
Failed Forms Submitted	1	4%
Total	25	100%

Top Referring Sites

This section identifies the domain names or numeric IP addresses with links to the site. This information will only be displayed if your server is logging this information.




Top Referring Sites

	Site	User Sessions
1	http://www.genomesecurities.com/	106
2	No Referrer	94
3	http://www.emedtrade.com/	40
4	http://emedtrade.com/	26
5	http://www.genomesecurities.com./	16
6	http://www.netcraft.com/	3
7	http://www.biospace.com/	1
Sub Total for the Referring Sites Above		286
Total for the Log File		286

Top Referring URLs

This section provides the full URLs of the sites with links to the site. This information will only be displayed if your server is logging the referrer information.

Top Referring URLs




Top Referring URLs

	URL	User Sessions
1	No Referrer	94
2	http://www.genomesecurities.com/	83
3	http://www.emedtrade.com/cistron/idxcontents.htm	14
4	http://www.genomesecurities.com./	13
5	http://www.genomesecurities.com/index.html	11
6	http://emedtrade.com/cistronrequest.htm	10

7	http://emedtrade.com/cistronrequestmain.htm	9
8	http://www.emedtrade.com/	6
9	http://emedtrade.com/idxbanner.htm	5
10	http://www.emedtrade.com/cistron/idxmain.htm	4
11	http://www.emedtrade.com/cistron/financialcontents.htm	4
12	http://www.emedtrade.com/cistron/	3
13	http://www.netcraft.com/	3
14	http://www.genomesecurities.com/Principals/principals.html	2
15	http://www.emedtrade.com/cistron/intellectualcontents.htm	2
16	http://emedtrade.com/cfscrip/processform.cfm	2
17	http://www.genomesecurities.com/Transactions/transactions.html	2
18	http://www.emedtrade.com/cistron	2
19	http://www.emedtrade.com/_private/stats/yesterday_01_b.html	2
20	http://www.genomesecurities.com/Search/search.html	1
Sub Total for the Referrers Above		272
Total for the Log File		286

Most Used Browsers

This section identifies the most popular WWW Browsers used by visitors to the site. This information will only be displayed if your server is logging the browser/platform information.



Most Used Browsers				
	Browser	Hits	% of Total Hits	User Sessions
1	Microsoft Internet Explorer	3,101	70.2%	157
2	Netscape	1,155	26.14%	67
3	Other Netscape Compatible	115	2.6%	42
4	MSProxy/2.0	27	0.61%	14


5	minixpc/0.9	11	0.24%	1
6	Others	7	0.15%	4
7	Lotus-Notes/4.5 (Windows-NT)	1	0.02%	1
	Total For Browsers Above	4,417	100%	286

Glossary

Glossary	
Ad Clicks	A click on an advertisement on a web site which takes a user to another site, it is referred to as an ad click.
Ad Views	A web page that presents an ad. Once the visitor has viewed an ad, he/she can click on it (see Ad Click). There may be more than one ad on an ad view.
Authentication	Technique by which access to Internet or Intranet resources requires the user to identify himself or herself by entering a username and password.
Bandwidth	Measure (in kilobytes of data transferred) of the traffic on the site.
Browser	A program used to locate and view HTML documents (Netscape, Mosaic, Microsoft Explorer, for example.)
Click through rate	Percentage of users who click on a viewed advertisement. This is a good indication of the effectiveness of this ad.
Client	The browser (see above) used by a visitor to a Web site.
Client Errors	An error occurring due to an invalid request by the visitor's browser. Client errors are in the 400-range. See "Return Code" definition.
Company Database	The database installed and used by WebTrends to look up the company name, city, state and country corresponding to a specific domain name.
Cookies	Persistent Client-State HTTP Cookies are files containing information about visitors to a web site (e.g., user name and preferences). This information is provided by the user during the first visit to a Web server. The server records this information in a text file and stores this file on the visitor's hard drive. When the visitor accesses the same web site again, the server looks for the cookie and configures itself based on the information provided.
Domain Name	The text name corresponding to the numeric IP address of a computer on the Internet (i.e., www.webtrends.com).
Domain Name Lookup	The process of converting a numeric IP address into a text name (for example, 204.245.240.194 is converted to www.webtrends.com).
FTP	File Transfer Protocol is a standard method of sending files between computers over the Internet.
Filters	A means of narrowing the scope of a report or view by specifying ranges or types of data to include in or exclude.
Forms	An HTML page which passes variables back to the server. These pages are used to gather information from users. Also referred to as scripts.
GIF	Graphics Interchange Format is an image file format commonly used in HTML documents.
HTML	Hyper Text Markup Language is used to write documents for the World Wide Web to specify hypertext links between related objects and documents.
HTTP	Hyper Text Transfer Protocol is a standard method of transferring data between a Web server and a Web browser .
Hit	An action on the Web site, such as when a user views a page or downloads a file.
Home Page	The main page of a Web site. The home page provides visitors with an overview and links to the rest of the site. It often contains or links to a Table of contents for the site.

Home Page URL	The local path or Internet URL to the default page of the Web site for which WebTrends reports will be generated.
IP Address	Internet Protocol address identifying a computer connected to the Internet.
Log File	A file created by a web or proxy server which contains all of the access information regarding the activity on that server.
Page Views	Also called Page Impressions. Hit to HTML pages only (access to non-HTML documents are not counted).
Platform	The operating system (i.e. Windows 95, Windows NT, etc.) used by a visitor to the site.
Protocol	An established method of exchanging data over the Internet.
Referrer	URL of an HTML page that refers to the site.
Return Code	<p>The return status of the request which specifies whether the transfer was successful and why.</p> <p>Possible "Success" codes are:</p> <ul style="list-style-type: none"> 200 = Success: OK 201 = Success: Created 202 = Success: Accepted 203 = Success: Partial Information 204 = Success: No Response 300 = Success: Redirected 301 = Success: Moved 302 = Success: Found 303 = Success: New Method 304 = Success: Not Modified <p>Possible "Failed" codes are:</p> <ul style="list-style-type: none"> 400 = Failed: Bad Request 401 = Failed: Unauthorized 402 = Failed: Payment Required 403 = Failed: Forbidden 404 = Failed: Not Found 500 = Failed: Internal Error 501 = Failed: Not Implemented 502 = Failed: Overloaded Temporarily 503 = Failed: Gateway Timeout
Server	A computer that hosts information available to anyone accessing the Internet.
Server Error	An error occurring at the server. Web server errors have codes in the 500 range.
Spiders	An automated program which searches the internet.
Suffix (Domain Name)	<p>The three digit suffix of a domain can be used to identify the type of organization.</p> <p>Possible "Suffixes" are:</p> <ul style="list-style-type: none"> .com = Commercial .edu = Educational .int = International .gov = Government .mil = Military .net = Network .org = Organization

URL	Uniform Resource Locator is a means of identifying an exact location on the Internet. For example, http://www.webtrends.com/html/info/default.htm is the URL which defines the use of HTTP to access the Web page Default.htm in the /html/info/ directory on the WebTrends Corporation Web site). As the previous example shows, a URL is comprised of four parts: Protocol Type (HTTP), Machine Name (webtrends.com), Directory Path (/html/info/), and File Name (default.htm).
User Agent	Fields in an extended Web server log file identifying the browser and platform used by a visitor.
User Session	A session of activity (all hits) for one user of a web site. A unique user is determined by the IP address or cookie. By default, a user session is terminated when a user is inactive for more than 30 minutes. This duration can be changed from General panel in the Options, Web Log Analysis dialog. Synonym: Visit.
View,Page	Each request for a particular web page which displays an ad. Also referred to as an impression.
Visit	Commonly called User Session. All activity for one user of a web site. By default, a user session is terminated when a user is inactive for more than 30 minutes.



This report was generated by WebTrends.

WebTrends is a registered trademark and CommerceTrends is a trademark of WebTrends Corporation. Other trademarks are the property of their respective owners.